

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2016226097 B2

(54) Title
scFv-Fc dimers that bind Transforming Growth Factor-Beta1 with high affinity, avidity and specificity

(51) International Patent Classification(s)
C07K 16/00 (2006.01) **C07K 16/22** (2006.01)

(21) Application No: **2016226097** (22) Date of Filing: **2016.03.03**

(87) WIPO No: **WO16/141244**

(30) Priority Data

(31) Number **62/128,133** (32) Date **2015.03.04** (33) Country **US**

(43) Publication Date: **2016.09.09**
(44) Accepted Journal Date: **2022.01.13**

(71) Applicant(s)
Genzyme Corporation

(72) Inventor(s)
Qiu, Huawei;Pan, Clark;Bird, Julie

(74) Agent / Attorney
AJ PARK, Level 24, Tower 2, Darling Park 201 Sussex St, Sydney, NSW, 2000, AU

(56) Related Art
US 6492497 B1
Bujak et al., In: Ossipow V. and Fischer N. (eds) **Monoclonal Antibodies. Methods in Molecular Biology (Methods and Protocols)** (2014) vol. 1131, p. 315-334, e-pub: Jan. 24, 2014.
POWERS D.B. et al., **Expression of single-chain Fv-Fc fusions in Pichia pastoris**, **Journal of Immunological Methods**, 2001, Vol.251, Issues 1-2, pp.123-135.
HOLLIGER PHILIPP ET AL, "ENGINEERED ANTIBODY FRAGMENTS AND THE RISE OF SINGLE DOMAINS", **NATURE BIOTECHNOLOGY**, GALE GROUP INC, (2005-09-01), vol. 23, no. 9, doi:10.1038/NBT1142, ISSN 1087-0156, pages 1126 - 1136
OLAFSEN T ET AL, "Antibody Vectors for Imaging", **SEMINARS IN NUCLEAR MEDICINE**, GRUNE AND STRATTON, ORLANDO, FL, US, vol. 40, no. 3, ISSN 0001-2998, (2010-05-01), pages 167 - 181, (2010-03-27)
WO 2012/088461 A2

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 September 2016 (09.09.2016)

(10) International Publication Number
WO 2016/141244 A8

(51) International Patent Classification:
C07K 16/00 (2006.01) *C07K 16/22* (2006.01)

PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2016/020779

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

3 March 2016 (03.03.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/128,133 4 March 2015 (04.03.2015) US

(71) Applicant: GENZYME CORPORATION [US/US]; 500 Kendall Street, Cambridge, MA 02142 (US).

(72) Inventors: QIU, Huawei; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). PAN, Clark; 353 Dutton Road, Sudbury, MA 01776 (US). BIRD, Julie; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US).

(74) Agents: VELEMA, James, H. et al.; Lathrop & Gage LLP, 28 State Street, Boston, MA 02109 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

20 October 2016

(15) Information about Correction:

see Notice of 20 October 2016



WO 2016/141244 A8

(54) Title: scFv-Fc DIMERS THAT BIND TRANSFORMING GROWTH FACTOR- β 1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY

(57) Abstract: An scFv-Fc dimer binds and neutralizes TGF β 1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF β 1, and long *in vivo* half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.

TITLE OF THE INVENTION

**scFv-Fc DIMERS THAT BIND TRANSFORMING GROWTH
FACTOR- β 1 WITH HIGH AFFINITY, AVIDITY AND
SPECIFICITY**

5

RELATED APPLICATIONS

This patent application claims the benefit of U.S. Provisional Patent Application 62/128,133, filed March 4, 2015, which is incorporated herein by reference in its entirety.

10 BACKGROUND OF THE INVENTION

Technical Field

An antigen-binding dimer having two polypeptide monomers, each comprising a single-chain fragment variable molecule (scFv), a hinge, and an Fc molecule, exhibits high affinity and avidity to Transforming Growth Factor- β 1 (TGF β 1) but not to TGF β 2 or to TGF β 3. Compositions comprising the antigen-binding dimer and methods of using the same for treatment of diseases involving TGF β 1 activity are described.

Background

Many severe diseases are linked to malfunctions of the TGF β -induced signaling pathway. For instance, an increased tissue level of TGF β is believed to be a factor in the development of idiopathic pulmonary fibrosis and myocardial fibrosis. Furthermore, high local tissue levels of TGF β may allow the maintenance and progression of some types of cancer cells. Down-regulation of TGF β signaling therefore may reduce the viability of such tumor cells.

25 TGF β isoforms are ~25 kDa homodimeric molecules with a similar structural framework in which two monomers are covalently linked via a disulfide bridge. The mammalian isoforms share a sequence identity of 70–82%, but have non-overlapping activities in vascular development and the regulation of immune cell function. Three TGF β isoforms have been reported in humans: TGF β 1, TGF β 2, and TGF β 3 (Swiss

Prot accession numbers P01137, P08112, and P10600, respectively). TGF β 1 and TGF β 3 trigger a cellular signaling cascade upon binding to the extracellular domains of two transmembrane receptors, known as TGF β receptor types I and II. TGF β 2 may bind to TGF β receptor types I and II, as well as TGF β receptor type III.

5 Antibodies that can bind human TGF β 1, TGF β 2, and TGF β 3 have been tested for clinical use. For instance, Grütter et al. disclosed GC1008, a human IgG4 monoclonal antibody (Mab; i.e., GC1008) in clinical development for treating malignancy and fibrotic diseases. *Proc. Nat'l Acad. Sci. USA* 105(51): 20251-56 (2008). GC1008 is a “pan-specific” TGF β neutralizing antibody, because it can 10 neutralize all three human TGF β isoforms. Antibodies that selectively neutralize TGF β 1 are disclosed, for example, in U.S. Patent No. 6,492,497 and U.S. Patent No. 7,151,169, which are incorporated by reference into this disclosure. Metelimumab, also known as CAT192 (IgG4), is a human IgG4 monoclonal antibody that selectively neutralizes TGF- β 1. See e.g., U.S. Patent No. 6,492,497. Metelimumab was tested 15 for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma, but demonstrated insufficient efficacy.

20 In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents, or such sources of information, is not to be construed as an admission that such documents, or such 25 sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.

25 In the description in this specification reference may be made to subject matter which is not within the scope of the appended claims. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the appended claims.

30 SUMMARY OF THE INVENTION

In a first aspect, the present invention provides an isolated binding protein that binds TGF β 1, wherein the isolated binding protein is a dimer formed from a polypeptide chain having the formula of, from N-terminus to C-terminus:

(VH domain)-(linker1)-(VL domain)-(linker2)-(hinge)-(Fc region),

wherein

the VH domain comprises a heavy chain complementarity determining region (HCDR) 1 having the amino acid sequence of SEQ ID NO: 22, an HCDR2 having the 5 amino acid sequence of SEQ ID NO: 23, and an HCDR3 having the amino acid sequence of SEQ ID NO: 24, 25, 26, or 30; and the VL domain comprises a light chain complementarity determining region (LCDR) 1 having the amino acid sequence of SEQ ID NO:27 with an A2S substitution, an LCDR2 having the amino acid sequence of SEQ ID NO: 28, and an LCDR3 having the amino acid sequences of SEQ 10 ID NO: 29;

the linker 1 is a [G₄S]₃-type linker;

the linker 2 is SEQ ID NO: 20 or a variant thereof, wherein the variant differs 15 from SEQ ID NO: 20 in length by one to four amino acids, or differs from SEQ ID NO: 20 by

having up to two amino acid substitutions from glycine to serine or from serine to glycine; and

the hinge comprises an amino acid sequence from a human IgG₁ or IgG₄ hinge region, or the amino acid sequence of SEQ ID NO: 7 or 21; and

20 the Fc region is derived from a human IgG1 or a human IgG4.

In a second aspect, the invention provides a pharmaceutical composition comprising the isolated binding protein of the first aspect and a pharmaceutically acceptable excipient.

In a third aspect, the invention provides an isolated polynucleotide encoding the isolated binding protein of the first aspect.

5 In a fourth aspect, the invention provides a vector comprising the isolated polynucleotide of the third aspect.

In a fifth aspect, the invention provides a host cell comprising the vector of the fourth aspect.

10 In a sixth aspect, the invention provides a method of making an isolated binding protein, comprising culturing the host cell of the fifth aspect under conditions suitable to produce the binding protein.

15 In a seventh aspect, the invention provides a method of treating a disease characterized by TGF β 1 expression in a human in need thereof, comprising administering to the human a therapeutically effective amount of the isolated binding protein of the first aspect, or the pharmaceutical composition of the second aspect.

20 In an eighth aspect, the invention relates to the use of the isolated binding protein of the first aspect in the preparation of a medicament for treating a disease characterized by TGF β 1 expression in a human in need thereof.

BRIEF DESCRIPTION OF THE INVENTION

25 Described herein are TGF β 1-binding scFv-Fc dimers that are capable of selectively neutralizing human TGF β 1. In one embodiment, the scFv-Fc dimers are formatted as scFv-Fc fusion proteins comprised of two polypeptide monomers, each

monomer comprising a single-chain Fv region (scFv), a hinge, and an Fc region. The VH and VL domains of the scFv-Fc dimer exhibit a higher affinity and avidity to TGF β 1 and more effectively neutralize TGF β 1 than when used in the IgG1 or IgG4 format.

5 In one embodiment, the scFv component may be composed of the same VH and VL domains as the VH and VL domains of metelimumab. The variable domains in the scFv component may be linked together by a linker, *e.g.*, a [G₄S]₃-type linker. Each of the scFv components of the scFv-Fc dimers may be fused via a hinge region, *e.g.*, a human IgG1 or IgG4 hinge region, to an Fc region. The monomers of the
10 dimer may be covalently linked by a disulfide bond between cysteine residues in the hinge region. In another embodiment, the scFv-Fc dimers may have structural dissimilarities to metelimumab, most notably the absence of CH₁ and CL domains and the presence of a linker between the VH and VL domains. Advantageously, the scFv-Fc dimers display an apparent affinity toward TGF β 1 nearly two orders of magnitude
15 greater than that of an scFv comprising the same VH and VL domains (CAT191(scFv), shown in SEQ ID NO: 12) in an A549 cell potency bioassay. Further, the scFv-Fc dimers display an apparent affinity toward TGF β 1 over three orders of magnitude greater than that of an IgG-formatted antibody comprising the same VH and VL domains (*e.g.*, CAT192) in the A549 cell bioassay. The scFv-Fc
20 dimers also display desirable stability and pharmacokinetic properties. Because of their relatively small size and extended half-life in serum, the scFv-Fc dimers are particularly useful for therapeutic applications.

Accordingly, described is an isolated binding protein comprising a variable domain that is capable of binding TGF β 1, wherein the binding protein exhibits a K_d for human TGF β 1 at least about 50% lower than the K_d of the same binding protein for human TGF β 2, as measured by surface plasmon resonance.

In another embodiment, described is an isolated binding protein comprising a variable domain that is capable of binding TGF β 1, wherein the binding protein exhibits a K_d for human TGF β 1 at least about 50% lower than the K_d of the same binding protein for human TGF β 3, as measured by surface plasmon resonance.

In a further embodiment, described is an isolated binding protein comprising a variable domain that is capable of binding TGF β 1, wherein the binding protein

exhibits a Kd for human TGF β 1 at least about 50% lower than the Kd of the same binding protein for human TGF β 2, and at least about 50% lower than the Kd of the same binding protein for human TGF β 3, as measured by surface plasmon resonance.

In a further embodiment, described is an isolated binding protein that binds
5 TGF β 1, wherein the binding protein comprises a first polypeptide chain and a second polypeptide chain, the first and the second polypeptide chains each having the formula of:

(VD₁)-(linker1)_n-(VD₂)-(linker2)_m-(hinge)_p-(Fc region),

wherein VD₁ comprises a first variable domain selected from the group
10 consisting of a VL domain isolated from an antibody capable of binding TGF β 1, and a VH domain isolated from an antibody capable of binding TGF β 1, and VD₂ comprises a second variable domain selected from the group consisting of a VL domain isolated from an antibody capable of binding TGF β 1, and a VH domain isolated from an antibody capable of binding TGF β 1; and wherein, n is 0 or 1, m is 0
15 or 1, and p is 0 or 1.

In one embodiment, described is an isolated TGF β 1-binding scFv-Fc dimer that selectively binds TGF β 1. The scFv-Fc dimer may comprise two polypeptide monomers, each having the following formula, from N-terminal to C-terminal: (VH domain)-(linker)-(VL domain)-(hinge)-(Fc region). In another embodiment, an
20 isolated binding protein that binds TGF β 1 is disclosed, which comprises a first polypeptide chain and a second polypeptide chain. The first and the second polypeptide chains may both have the formula of, from N-terminal to C-terminal: (VH domain)-(linker1)_n-(VL domain)-(linker2)_m-(hinge)_p-(Fc region). p may be 0 or 1, n may be 0 or 1, and m may be 0 or 1. In one embodiment, the first and second
25 polypeptide chains may be identical and may form a dimer.

In another embodiment, the disclosed TGF β 1 binding protein may comprise a polypeptide chain having the formula of, from N-terminal to C-terminal: (VH domain)-(linker1)_n-(VL domain)-(linker2)_m-(hinge)_p-(Fc region), wherein p may be 0 or 1, n may be 0 or 1, and m may be 0 or 1.

30 The VH domain of the disclosed binding protein may comprise a variable heavy complementarity determining region 1 (HCDR1), a variable heavy complementarity determining region 2 (HCDR2), and a variable heavy

complementarity determining region 3 (HCDR3). In one aspect, the HCDR1 may have the amino acid sequence of SEQ ID NO: 22, The HCDR2 may have the amino acid sequence of SEQ ID NO: 23, and the HCDR3 may have the amino acid sequence of SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO: 30.

5 The framework regions of the VH domain may be selected from a variable heavy germline sequence. The VH domain may be selected, for example, from the human VH domain sequences set forth in SEQ ID NO: 1 or SEQ ID NO: 2, or a variant thereof having modifications in up to four amino acids.

10 The VL domain of the disclosed binding protein may comprise a variable light complementarity determining region 1 (LCDR1), a variable light complementarity determining region 2 (LCDR2), and a variable light complementarity determining region 3 (LCDR3). In one aspect, the LCDR1 may have the amino acid sequence of SEQ ID NO: 27, the LCDR2 may have the amino acid sequence of SEQ ID NO: 28, and the LCDR3 may have the amino acid sequence of SEQ ID NO: 29.

15 The framework regions of the VL domain may be selected from a variable lambda or kappa germline sequence. The VL domain may be selected, for example, from the human $\text{V}\kappa$ domain sequences set forth in SEQ ID NO: 5 or SEQ ID NO: 6, or a variant thereof having modifications of up to four amino acids. In one embodiment, each polypeptide of the dimer may comprise the VH domain set forth in
20 SEQ ID NO: 1 and the $\text{V}\kappa$ domain set forth in SEQ ID NO: 5, which are the VH and VL domains present in metelimumab, respectively.

25 In one embodiment, the variable domains in the scFv component may be linked by a flexible linker about 15 amino acids in length. "About" in this context means the linker can vary by up to plus or minus four amino acids in length. For optimal flexibility, the linker is composed predominantly of glycine and serine residues. For example, the linker may be a $[\text{G}_4\text{S}]_3$ -type linker. The linker may have the amino acid sequence SGGGSGGGGSGGGGS (SEQ ID NO: 3), the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO: 4), or a variant thereof having up to four amino acid modifications. For purpose of this disclosure, "having up to x amino acids modifications" means that the up to x number of amino acids may be changed to different amino acids by one of skill in the art without significantly altering the structure and function of the polypeptide.

In another embodiment, p is 1 and the scFv component is connected to an Fc region by a hinge. The hinge may comprise amino acid sequences derived from a human IgG1 or IgG4 hinge region. For example, the hinge may comprise the amino acid sequence PKSCDKTHTCPPCPAPELLGGP (SEQ ID NO: 7), or a variant thereof having up to four amino acid modifications. In one embodiment, the hinge length may vary from 3-15 amino acids. When the hinge is from a human IgG1, it may comprise the amino acid sequence CPPCP (SEQ ID NO: 21). Further, the variant of the hinge of SEQ ID NO: 7, which is also a human IgG1 hinge, may comprise the amino acid sequence CPPCP (SEQ ID NO: 21).

10 In another embodiment, m is 1 and a linker2 is present between scFv component and the hinge. In one aspect, linker2 may comprise the amino acid sequence GGSG (SEQ ID NO: 20), or a variant thereof having up to 2 amino acid modifications.

15 The Fc region may comprise two or three constant domains, e.g., a CH₂ domain and CH₃ domain. The Fc region may be obtained from a human IgG1, a human IgG4, or a variant of a human IgG1 or IgG4 having up to ten amino acid modifications, for example. In one embodiment, each polypeptide of the dimer has the sequence set forth in SEQ ID NO: 9. The structure of the scFv-Fc dimer of SEQ ID NO: 9 is shown in FIG. 2. The scFv-Fc dimer may bind TGF β 1 selectively. The 20 scFv-Fc dimer may show an apparent dissociation constant less than 1 nM or even less than 0.1 nM. The apparent dissociation constant may be measured by using an A549 bioassay or by surface plasmon resonance, for example.

25 In another embodiment, an isolated polynucleotide is disclosed which may comprise a nucleotide sequence encoding the scFv-Fc dimer. The isolated polynucleotide may be a cDNA, a recombinant DNA or a synthetic DNA. A host cell may comprise the isolated nucleic acid. The host cell may be a human cell, such as a Human Embryonic Kidney 293 (HEK293) cell and cell lines derived therefrom, or it may be a Chinese Hamster Ovary (CHO) cell. A method of making the scFv-Fc dimer may include culturing the host cell under suitable conditions to produce the 30 scFv-Fc dimer. The scFv-Fc dimer may be purified. The degree of purity may be 90%, 95%, 99%, 99.5% or more.

The scFv-Fc dimer of the present invention may be an element of a composition. The composition may be a pharmaceutical composition. The pharmaceutical composition may comprise a therapeutically effective amount of the scFv-Fc dimer. The composition may further comprise one or more biologically active components, excipients, or diluents.

A method of treating a disease or condition resulting directly or indirectly from TGF β 1 activity in a human may comprise administering a pharmaceutical composition comprising a therapeutically effective amount of the scFv-Fc dimer. The disease or condition may be selected from the group consisting of a fibrotic disease, cancer, an immune-mediated disease, e.g., diffuse cutaneous systemic sclerosis, bone remodeling disease, kidney disease and/or combinations thereof. The scFv-Fc dimer may be used in the manufacture of a medicament for treatment of a disease or disorder selected from the group consisting of a fibrotic disease, cancer, an immune-mediated disease, e.g., diffuse cutaneous systemic sclerosis, bone remodeling disease, kidney disease and/or combinations thereof. The treatment of the disease or disorder may comprise neutralizing TGF β 1 or inhibiting TGF β 1 signaling. The treatment of the disease or disorder may comprise inhibiting TGF β 1-mediated fibronectin production, vascular endothelial growth factor (VEGF) production, epithelial cell proliferation, endothelial cell proliferation, smooth muscle cell proliferation, or immunosuppression. The treatment of the disease or disorder may comprise increasing natural killer cell activity.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

The drawings presented herein are for purpose of illustration and are not to be used to limit the scope of the present invention.

FIG. 1 depicts the general structures of the various formats.

FIG. 2 depicts the results of a Biacore TGF β 1 binding assay which showed the loss of affinity when the scFv(CAT191) was converted into a full length IgG4 (CAT192) molecule.

FIG. 3 shows the results of an A549 cell bioassay comparing the inhibitory effects by various antibody constructs on TGF β 1-stimulated IL-11 production: scFv diabody 5aa (SEQ ID NO: 14); CAT191(scFv) (SEQ ID NO: 12); CAT191(scFv-Fc)

(SEQ ID NO: 9); and CAT192(IgG4) (light chain SEQ ID NO: 10 and heavy chain SEQ ID NO: 11).

FIG. 4 depicts the results of pharmacokinetic tests to determine the half-life of CAT191 (scFv-Fc) following intravenous (IV) administration.

5 FIG. 5 depicts the results of pharmacokinetic tests to determine the half-life of CAT191 (scFv-Fc) following intraperitoneal (IP) administration.

FIG. 6 shows the TGF β 1-specific binding results of CAT191(scFv-Fc) prepared from CHO cells.

10 FIG. 7 shows the the cell-based potency assay results of CAT191(scFv-Fc) prepared from CHO cells.

DETAILED DESCRIPTION OF THE INVENTION

The term “comprising” as used in this specification and claims means “consisting at least in part of”. When interpreting statements in this specification and claims which include the term “comprising”, other features besides the features 15 prefaced by this term in each statement can also be present. Related terms such as “comprise”, “comprises”, and “comprised” are to be interpreted in similar manner.

The disclosed scFv-Fc dimers bind and neutralize TGF β 1 selectively and with high affinity and avidity. The scFv regions may be composed of the same VH and 20 VL domains as in metelimumab. scFv-Fc dimers advantageously show greater efficacy in neutralizing TGF β 1 than when the variable domains are used in other formats. Because of their relatively small size and extended half-life in serum, the present scFv-Fc dimers are ideal candidates for therapeutic applications.

As used herein, a first element “and/or” a second element means a specific 25 disclosure of the first or second element separately, or the first and second elements in combination. The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.

An “isolated” polynucleotide (or nucleic acid) or protein is removed and/or altered from its natural form using genetic engineering technologies. A “purified” 30 nucleic acid or protein may be substantially pure, e.g., at least 90% pure, or in homogeneous form.

“Selective binding”, or "binding selectively" to human TGF β 1, means that the binding protein (e.g., scFv-Fc dimer) is capable of binding human TGF β 1 with a higher affinity than binding to human TGF β 2 or human TGF β 3, e.g., with a dissociation constant with human TGF β 1 at least 50% lower than its dissociation constant with human TGF β 2 or human TGF β 3, as measured by surface plasmon resonance.

scFv-Fc Dimers

In one embodiment, the present scFv-Fc dimer variable domains comprise complementarity determining regions (CDRs) from the CDRs disclosed in U.S. Patent No. 6,492,497 (e.g., SEQ ID NOs: 11-19 of U.S. Patent No. 6,492,497), incorporated herein by reference. The CDR regions are listed below:

	HCDR1	SYGMH	SEQ ID No. 22
	HCDR2	VISYDGSIKYYADSVKG	SEQ ID No. 23
	HCDR3	TGEYSGYDTSGVEL	SEQ ID No. 24
15		TGEYSGYDTDPQYS	SEQ ID No. 25
		TGFYSGYDTPASPD	SEQ ID No. 26
	LCDR1	RASQGIGDDLG	SEQ ID No. 27
	LCDR2	GTSTLQS	SEQ ID No. 28
20	LCDR3	LQDSNYPLT	SEQ ID No. 29

Surprisingly, a consensus HCDR3 binding motif is revealed, having the sequence:

HCDR3 TG_{X₁}YSGYDTX_{X₂}X_{X₃}X_{X₄}X_{X₅}X_{X₆} SEQ ID No. 30

Wherein: X₁ may be any amino acid (preferably E, or F), or absent,
X₂ may be any amino acid (preferably S, D, or P), or absent,
25 X₃ may be any amino acid (preferably G, P, or A), or absent,
X₄ may be any amino acid (preferably V, Q, or S), or absent,
X₅ may be any amino acid (preferably E, Y, or P), or absent,
X₆ may be any amino acid (preferably L, S, or D), or absent.

The VH domain comprises the HCDR1 of SEQ ID No. 22, the HCDR2 of SEQ ID No. 23, and one of the HCDR3s selected from the group consisting of SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, and SEQ ID No. 30. The CDR sequences may be separated by anywhere from one to four framework regions, in order from the N-terminal: FW1 – CDR1 – FW2 – CDR2 – FW3 – CDR3 – FW4.

The framework regions of the VH domain may be selected from a variable heavy germline sequence. In one embodiment, the FW region sequences may be selected from the same human variable heavy germline sequence. The VL domain comprises the LCDR1 of SEQ ID NO: 7, the LCDR2 of SEQ ID NO: 28, and the LCDR3 of SEQ ID NO: 29. The framework regions of the VL domain may be selected from a variable lambda or kappa germline sequence, e.g., from the same human variable lambda or kappa germline sequence. At present, about 40 variable heavy germline sequences are known in the art, as are about 40 variable kappa germline sequences and about 30 variable lambda germline sequences, e.g., V_H3, V_K1, V_H 1-69, and V_H 1-10 e.

In another embodiment, composite VH or VL domains may be generated by using the CDR sequences disclosed herein. For example, crystal structures of the VH or VL domains may be used as a guidance to generate composite domain using CDR sequences from one antibody and using the germline FW regions from another antibody. More details can be found in U.S. Patent Application Publication No. 20020099179; and Homes and Foote, J Immunol. 1997 Mar 1;158(5):2192-201, both of which are hereby incorporated into this disclosure by reference.

The present scFv-Fc dimers may be composed of the same VH and VL domains as in metelimumab, having the sequences set forth in SEQ ID NO: 1 and SEQ ID NO: 5, respectively. The VH domain may be replaced by the VH domain having the sequences set forth in SEQ ID NO: 2; the VL domain may be replaced by the VL domain having the sequences set forth in SEQ ID NO: 6. These VH and VL domains are disclosed in U.S. Patent No. 6,492,497 (e.g., SEQ ID NOS: 4, 6, 8, and 10), incorporated herein by reference.

A “variable domain” (VD) refers to a hypervariable binding domain of an immunoglobulin, or a ligand binding domain of a receptor, involved in antigen/ligand binding as is known by persons skilled in the art. Variable domains are routinely referred to by their location or origin within an immunoglobulin; e.g., variable domains of the light chain of an immunoglobulin (VL), variable domains of the heavy chain of an immunoglobulin (VH), variable domains of the heavy chain of a camelid immunoglobulin (VHH).

A “variant” variable domain comprises amino acid additions, substitutions, and/or deletions, compared to the reference sequence. A “variant” of the VH or VL

domains may have up to four such amino acid modifications. For example, one of the two domains may comprise an amino acid substitution, while the other domain is unmodified, or both of the domains may comprise amino acid substitutions.

5 Modifications that add or delete amino acid residues may be made at the N-terminus or C-terminus of the VH or VL domain. For example, the N-terminal residue of the VH domain may be deleted.

Up to four amino acid substitutions may be made to de-immunize the scFv-Fc dimer, for example. De-immunization can be performed according to the method of Harding et al. (2010) *mAbs* 2: 256-265, for example.

10 Framework residues of the VH and/or VL domains, for example, may be substituted to increase the stability of the scFv-Fc dimers and/or decrease their tendency to aggregate. Poor stability can affect the ability of the expressed scFv-Fc dimers to fold properly when recombinantly expressed, resulting in a fraction of the expressed antibodies being non-functional. Low stability antibodies also may be
15 prone to forming potentially immunogenic aggregates or may have impaired avidity or shelf-life. scFv polypeptides in particular may demonstrate problems with stability, solubility, expression, aggregation, breakdown products, and overall manufacturability in both bacterial and mammalian expression systems. Framework amino acid substitutions that are expected to increase the stability and/or decrease the
20 tendency to aggregate of a VH and/or VL domain, e.g., in an scFv polypeptide, are disclosed in WO 2007/109254, for example. Substitutions in corresponding residues in the present VH and VL domains are expected similarly to increase stability and/or decrease the tendency of scFv-Fc dimers to aggregate.

Substitutions that can be tolerated are expected to include those that would
25 replace an amino acid of SEQ ID NO: 1, 2, 5, or 6 with a corresponding amino acid that occurs in another human VH or VL domain germline sequence. A substitution of a framework amino acid with an amino acid occurring in any of these germline sequences may be tolerated. For example, a residue of a VH domain of SEQ ID NO: 1 could be substituted with an amino acid appearing in a corresponding position
30 in any VH germline sequence, e.g., the germline sequence from DP-10 (V_H 1-69) or DP-88 (V_H 1-e). Corresponding positions in this case are determined by a sequence alignment between the various germline sequences, using alignment techniques well known in the art, e.g., ClustalW.

Additional substitutions that are expected to be tolerated are those made to an amino acid with most of its side chain exposed to the solvent, as determined by analysis of the three co-crystal structures. The solvent-accessible surface area of a residue may be estimated using techniques well known in the art. Further, it is 5 expected that substitutions to amino acids buried within the variable domains will be better tolerated if the side chain of the amino acid does not create steric hindrance with adjoining residues. For this reason, buried amino acids generally are substituted with amino acids with side chains of similar or smaller size. For example, a substitution of a buried Ile residue with a Leu, Val, Ala, or Gly is expected to be 10 tolerated. Possible steric hindrance created by a substitution can be predicted by analysis of the three co-crystal structures. Further substitutions that are expected to be tolerated are those maintaining existing electrostatic interactions within the variable domains, e.g., dipole-dipole interactions, induced dipole interactions, hydrogen bonds, or ionic bonds.

15 Additional amino acid substitutions of variable domains include those expected to confer new useful properties to the antibodies or antigen-binding fragments thereof. For example, putative N-glycosylation sites in the VH and/or VL domains can be removed to prevent or reduce the formation of N-glycoforms. The amino-terminal residue can be substituted with a Gln residue to cause 20 pyroglutamylation, which can decrease the number of charge variants. Amino acid substitutions can be used to lower the isoelectric point, which can decrease the rate of elimination of IgG polypeptide antibodies, for example.

25 Surface residues of variable domains can be substituted with Cys or Lys residues, for example, which then can be covalently modified and coupled to molecules conferring useful characteristics to the antibodies or antigen-binding fragments thereof, e.g., a detectable label, toxin, targeting moiety, or protein. For example, Cys residue can be coupled to a cytotoxic drug to form a drug conjugate. Cys residues also can be coupled to molecules that increase the serum half-life, e.g., 30 polyethylene glycol (PEG) or serum albumin. Such amino acid modifications are reviewed in Beck et al. (2010) *Nature* 10: 345-52, for example.

Detectable labels include radiolabels such as ^{131}I or ^{99}Tc , which may be attached to antibodies or antigen-binding fragments thereof using methods known in the art. Labels also include enzyme labels such as horseradish peroxidase. Labels

further include chemical moieties such as biotin which may be detected via binding to a specific cognate detectable moiety, e.g., labeled avidin. Other moieties can be attached that facilitate purification. For example, antibodies or antigen-binding fragments thereof can be His-tagged using well-known methods of recombinant 5 modification and expression.

The VH and VL domains of the scFv-Fc dimers are linked together by a linker, termed Linker1 herein. Linkers suitable for making an scFv fragment are well known in the art. *See, e.g.*, Bird et al. (1988) *Science*, 242: 423-426; Huston et al. (1988) *Proc. Nat'l Acad. Sci. USA* 85: 5879-5883. This can be accomplished by 10 fusing the encoding nucleic acids in-frame and expressing the fusion protein in a suitable host cell, for example. Suitable linkers include those of the [G₄S]₃-type. The [G₄S]₃-type linkers are composed of repeating units of glycine and serine residues. Such linkers may have a sequence of SGGGSGGGGGSGGGGS (SEQ ID NO: 3) or GGGGSGGGGGSGGGGS (SEQ ID NO: 4) or a variant thereof having up to four 15 amino acid modifications, for example. Modifications can include deletions or insertions that change the linker length, or amino acid substitutions, preferably from Gly to Ser or vice versa. [G₄S]₃-type linkers have been widely used to link variable domains in an scFv structure, because the linkers are hypoallergenic and causes minimal conformational distortions to the variable domains. *See, e.g.*, Huston et al. 20 (1988) *Proc. Natl. Acad. Sci. USA* 85: 5879-83.

In the scFv-Fc dimers, a short linker sequence, termed Linker2 herein, is optionally inserted between the VL domain and the hinge. This linker sequence increases the flexibility of the scFv component with respect to the Fc component. In one embodiment, Linker2 has the sequence of GGSG (SEQ ID NO: 20). Suitable 25 modifications to the GGSG linker include altering its length by one to four amino acids or substituting one to two amino acids, preferably from Gly to Ser or vice versa.

The hinge region is a flexible domain that joins the scFv portion to the Fc region. The flexibility of the hinge region in IgG and IgA molecules allows the Fab arms to adopt a wide range of angles, permitting binding to epitopes spaced variable 30 distances apart. A suitable hinge region includes, for example, the human IgG1 hinge region having the amino acid sequence PKSCDKTHTCPPCPAPELLGGP (SEQ ID NO: 7). This sequence corresponds to a portion of the human IgG1 upper hinge, the middle hinge, and an N-terminal portion of the CH₂ domain, as disclosed in FIG. 4B

of U.S. Patent No. 8,048,421, for example. The hinge from a human IgG1 contains two Cys residues, which can form disulfide bonds with the Cys residues of the hinge on the corresponding monomer. The human IgG1 hinge portion that forms the disulfide bonds contains the amino acid sequence CPPCP (SEQ ID NO: 21). Variants 5 of a human IgG1 hinge may comprise this sequence.

The scFv component is fused in frame to an Fc region, which forms the Fc component of the dimer. Suitable Fc regions contain two or three constant regions. Fc regions include those from human IgG1, as set forth in SEQ ID NO: 8, or IgG4, as set forth in the CH₂ and CH₃ domains of SEQ ID NO: 11. The Fc region of an 10 antibody mediates its serum half-life and effector functions, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP).

Modifications can be made to the hinge and Fc region to improve various properties of the scFv-Fc dimers. In one embodiment, one, two, three, four, five or 15 up to ten amino acids of a naturally occurring human Fc region can be modified, in addition to modifications of the hinge region. For example, the Fc region can be modified to increase the serum half-life of the scFv-Fc dimer. The half-life of an IgG depends on its pH-dependent binding to the receptor FcRn. FcRn, which is expressed on the surface of endothelial cells, binds the IgG in a pH-dependent manner and 20 protects it from degradation. Mutations located at the interface between the CH₂ and CH₃ domains, for example, have been shown to increase the binding affinity to FcRn and the half-life of IgG1 *in vivo*. Such modifications are reviewed in Strohl WR., 2009. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr 25 Opin Biotechnol. 20(6):685-91; and Vaccaro C. et al., 2005. Engineering the Fc region of immunoglobulin G to modulate *in vivo* antibody levels. Nat Biotechnol. 23(10):1283-8, for example.

Other modifications to the hinge and/or Fc region can increase or reduce 30 effector functions. The four human IgG isotypes bind the activating Fc γ receptors (Fc γ RI, Fc γ RIIa, Fc γ RIIIa), the inhibitory Fc γ RIIb receptor, and the first component of complement (C1q) with different affinities, resulting in different effector functions. Binding of IgG to the Fc γ Rs or C1q, for example, depends on residues located in the IgG hinge region and CH₂ domain. Single or multiple amino acid substitutions of these residues can affect effector function by modulating the IgG interaction with

Fc γ Rs or C1q. Other substitutions are known to affect effector function. These modifications are reviewed in Strohl (2009) “Optimization of Fc-mediated effector functions of monoclonal antibodies,” *Curr. Opin. Biotechnol.* 20:685-91, for example.

5 Representative modifications of the hinge and/or Fc region are summarized in
Table 1.

Table 1: Representative Hinge and Fc Region Modifications

Isotype	Species	Substitutions	FcR/C1q Binding	Effector Function	Refs
IgG1	Human	T250Q/M428L	Increased binding to FcRn	Increased half-life	1
IgG1	Human	1M252Y/S254T/T256E + H433K/N434F	Increased binding to FcRn	Increased half-life	2
IgG1	Human	E233P/L234V/L235A/G236 + A327G/A330S/P331S	Reduced binding to Fc γ RI	Reduced ADCC and CDC	3, 4
IgG1	Human	E333A	Increased binding to Fc γ RIIIa	Increased ADCC and CDC	5, 6
IgG1	Human	S239D/A330L/I332E	Increased binding to Fc γ RIIIa	Increased ADCC	7, 8
IgG1	Human	P257I/Q311	Increased binding to FcRn	Unchanged half-life	9
IgG1	Human	K326W/E333S	Increased binding to C1q	Increased CDC	10
IgG1	Human	S239D/I332E/G236A	Increased Fc γ RIIa/Fc γ RIIb ratio	Increased macrophage phagocytosis	11
IgG1	Human	K322A	Reduced binding to C1q	Reduced CDC	5
IgG4	Human	S228P	--	Reduced Fab-arm exchange	12
IgG2a	Mouse	L235E + E318A/K320A/K322A	Reduced binding to Fc γ RI and C1q	Reduced ADCC and CDC	10

1. Hinton et al. (2004) *J. Biol. Chem.* 279(8):6213-16.
2. Vaccaro et al. (2005) *Nature Biotechnol.* 23(10):1283-88.
3. Armour et al. (1999) *Eur. J. Immunol.* 29(8):2613-24.
4. Shields et al. (2001) *J. Biol. Chem.* 276(9):6591-604.
5. Idusogie et al. (2000) *J. Immunol.* 164(8):4178-84.
6. Idusogie et al. (2001) *J. Immunol.* 166(4):2571-75.
7. Lazar et al. (2006) *Proc. Nat'l Acad. Sci. USA* 103(11): 4005-10.
8. Ryan et al. (2007) *Mol. Cancer Ther.* 6: 3009-18.
9. Datta-Mannan et al. (2007) *Drug Metab. Dispos.* 35: 86-94.
10. Steurer et al. (1995) *J. Immunol.* 155(3):1165-74.
11. Richards et al. (2008) *Mol. Cancer Ther.* 7(8):2517-27.
12. Labrijn et al. (2009) *Nature Biotechnol.* 27(8):767-71.

Further, recombinant amino acid modifications can be used to decrease structural homogeneity of the expressed polypeptides. A representative example is Peters et al. (2012) *J. Biol. Chem.* 287(29): 24525-33, which discloses Cys to Ser substitutions in the IgG4 hinge region that reduce the disulfide bond heterogeneity and increase Fab domain thermal stability. Similarly, Zhang et al. (2010) *Anal. Chem.* 82: 1090-99 disclose engineering the IgG2 hinge region to limit disulfide bond scrambling and the formation of structural isomers in therapeutic applications. Amino acid modifications to a CH3 domain also can be used to delete carboxy-terminal Lys residues to decrease the number of charge variants. Amino acid modifications also can be used to improve the pharmacological function of recombinant antibodies or antigen-binding fragments thereof. For example, amino acid modifications can be used to increase complement activation, enhance antibody-dependent cellular cytotoxicity (ADCC) by increasing Fc γ RIIIA binding or decreasing Fc γ RIIIB binding, and/or increase serum half-life by increasing FcRn binding. Such amino acid modifications are reviewed in Beck et al. (2010) *Nature* 10: 345-52, for example.

Nucleic Acids and Methods of Making scFv-Fc Dimers

Also described are nucleic acids encoding scFv-Fc dimers. The isolated nucleic acid may be a synthetic DNA, a non-naturally occurring mRNA, or a cDNA, for example. Examples include the nucleic acids encoding the VH and VL domains set forth in SEQ ID NOS: 3, 5, 7, and 9 of U.S. Patent No. 6,492,497. Additional nucleic acids include the sequence set forth in SEQ ID NO: 13 described herein, which encodes the diabody-5aa set forth in SEQ ID NO: 14, and the sequence set forth in SEQ ID NO: 15, which encodes the leucine zipper peptide-derived dimer having the amino acid sequence set forth in SEQ ID NO: 16. Additional nucleic acids include the sequence set forth in SEQ ID NO: 17, which encodes CAT191(scFv-Fc), which has the amino acid sequence set forth in SEQ ID NO: 9. The nucleic acid may be inserted within a plasmid, vector, or transcription or expression cassette. The nucleic acids encoding the scFv-Fc dimers may be made and the expressed antibodies may be tested using conventional techniques well known in the art, such as disclosed in Borsi et al. (2002) *Int. J. Cancer* 102: 75-85.

A recombinant host cell may comprise one or more constructs above. Methods of preparing scFv-Fc dimers comprise expressing the encoding nucleic acid in a host cell under conditions to produce the scFv-Fc dimers, and recovering the antibodies. The process of recovering the antibodies may comprise isolation and/or purification of the antibodies. The method of production may comprise formulating the antibodies into a composition including at least one additional component, such as a pharmaceutically acceptable excipient.

The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which exogenous DNA has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell, but, to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. Preferably host cells include prokaryotic and eukaryotic cells selected from any of the Kingdoms of life. Preferred eukaryotic cells include protist, fungal, plant and animal cells. Most preferably host cells include but are not limited to the prokaryotic cell line *E. Coli*; mammalian cell lines CHO, HEK 293 and COS; the insect cell line Sf9; and the fungal cell *Saccharomyces cerevisiae*.

Suitable vectors comprising a nucleic acid encoding scFv-Fc dimers can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, phage, phagemids, adenoviral, AAV, lentiviral, for example. Techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells, and gene expression, are well known in the art.

The term "vector", as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector,

wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the 5 genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of 10 plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

15 Introducing such nucleic acids into a host cell can be accomplished using techniques well known in the art. For eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection, and transduction using retroviruses or other viruses, for example. For bacterial cells, suitable techniques may include calcium chloride transformation, 20 electroporation, and transfection using bacteriophage. The introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells under conditions for expression of the gene. In one embodiment, the nucleic acid of the invention is integrated into the genome, e.g., chromosome, of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the 25 genome, in accordance with standard techniques.

Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, plant cells, insect cells, fungi, yeast and transgenic plants and animals. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster 30 ovary (CHO) cells, HeLa cells, baby hamster kidney cells, mouse melanoma cells, rat myeloma cells, human embryonic kidney cells, e.g., HEK293 cells, human embryonic

retina cells, and many others. The expression of antibodies and antibody fragments in prokaryotic cells, such as *E. coli*, is well established in the art. For a review, see for example, Plückthun *Bio/Technology* 9: 545-551 (1991). Expression in cultured eukaryotic cells is also available to those skilled in the art, as reviewed in Andersen et al.

5 (2002) *Curr. Opin. Biotechnol.* 13: 117-23, for example.

scFv-Fc dimers may be glycosylated, either naturally or the choice of expression host, e.g., CHO, HEK293, or NSO (ECACC 85110503) cells, or they may be unglycosylated, for example if produced by expression in a prokaryotic cell. Glycosylation may also be intentionally altered, for example by inhibiting fucosylation, 10 in order to increase ADCC activity of the resulting scFv-Fc dimer.

Methods of Using Antibodies or Antigen-Binding Fragments Thereof

The scFv-Fc dimers may be used in a method of treatment or diagnosis of the human or animal body, such as a method of treatment (which may include prophylactic treatment) of a disease or disorder in a human patient, which comprises administering an effective amount to treat the patient. Treatable conditions include any in which TGF β 1 15 plays a role, e.g., a fibrotic disease, cancer, an immune-mediated disease, and wound healing, e.g., diffuse systemic sclerosis, bone remodeling disease, kidney disease and/or combinations thereof.

Antibodies specific for human TGF β 1 have been shown to be effective in animal 20 models for the treatment of TGF β 1 glomerulonephritis (Border et al. (1990) *Nature* 346: 371-374), neural scarring (Logan et al. (1994) *Eur. J. Neurosci.* 6: 355-363), dermal scarring (Shah et al. (1992) *Lancet* 339: 213-214; Shah et al. (1994) *J. Cell Science* 107: 1137-1157; Shah et al. (1995) *J. Cell Science* 108: 985-1002), and pulmonary fibrosis (Giri et al. (1993) *Thorax* 48: 959-966). Further, antibodies to TGF β 1, 2, and 3 have 25 been shown to be effective in models of lung fibrosis, radiation induced fibrosis (U.S. Patent No. 5,616,561), myelofibrosis, burns, Dupuytren's contracture, gastric ulcers, and rheumatoid arthritis (Wahl et al. (1993) *Exp. Medicine* 177: 225-230).

The scFv-Fc dimers are useful to treat a disease and condition resulting directly or 30 indirectly from TGF β 1 activity. The scFv-Fc dimers may selectively inhibit the activity of a human TGF β 1 isoform *in vitro* or *in vivo*. Activities of TGF β 1 isoforms include, but

are not limited to, TGF β -mediated signaling, extracellular matrix (ECM) deposition, inhibiting epithelial and endothelial cell proliferation, promoting smooth muscle proliferation, inducing Type III collagen expression, inducing TGF- β , fibronectin, VEGF, and IL-11 expression, binding Latency Associated Peptide, tumor-induced

5 immuno suppression, promotion of angiogenesis, activating myofibroblasts, promotion of metastasis, and inhibition of NK cell activity. For example, the scFv-Fc dimers are useful to treat focal segmental glomerulosclerosis (FSGS), hepatic fibrosis (HF), acute myocardial infarction (AMI), idiopathic pulmonary fibrosis (IPF), scleroderma (SSc), and Marfan Syndrome.

10 The scFv-Fc dimers are useful to treat diseases and conditions including, but not limited to, a fibrotic diseases (such as glomerulonephritis, neural scarring, dermal scarring, pulmonary fibrosis, lung fibrosis, radiation induced fibrosis, hepatic fibrosis, myelofibrosis), burns, immune mediated diseases, inflammatory diseases (including rheumatoid arthritis), transplant rejection, cancer, Dupuytren's contracture, and gastric 15 ulcers. They are also useful for treating, preventing and reducing the risk of occurrence of renal insufficiencies including but not limited to: diabetic (type I and type II) nephropathy, radiation-induced nephropathy, obstructive nephropathy, diffuse systemic sclerosis, pulmonary fibrosis, allograft rejection, hereditary renal disease (e.g., polycystic kidney disease, medullary sponge kidney, horseshoe kidney), glomerulonephritis, 20 nephrosclerosis, nephrocalcinosis, systemic lupus erythematosus, Sjogren's syndrome, Berger's disease, systemic or glomerular hypertension, tubulointerstitial nephropathy, renal tubular acidosis, renal tuberculosis, and renal infarction. In particular, they are useful when combined with antagonists of the renin-angiotensin-aldosterone system including, but not limited to: renin inhibitors, angiotensin-converting enzyme (ACE) 25 inhibitors, Ang II receptor antagonists (also known as "Ang II receptor blockers"), and aldosterone antagonists. Methods for using scFv-Fc dimers in combination with such antagonists are set forth in WO 2004/098637, for example.

The scFv-Fc dimers also are useful to treat diseases and conditions associated with the deposition of ECM, including, systemic sclerosis, postoperative adhesions, 30 keloid and hypertrophic scarring, proliferative vitreoretinopathy, glaucoma drainage surgery, corneal injury, cataract, Peyronie's disease, adult respiratory distress syndrome,

5 cirrhosis of the liver, post myocardial infarction scarring, post angioplasty restenosis, scarring after subarachnoid hemorrhage, multiple sclerosis, fibrosis after laminectomy, fibrosis after tendon and other repairs, scarring due to tattoo removal, biliary cirrhosis (including sclerosing cholangitis), pericarditis, pleurisy, tracheostomy, penetrating central nervous system injury, eosinophilic myalgic syndrome, vascular restenosis, veno-occlusive disease, pancreatitis and psoriatic arthropathy.

10 The scFv-Fc dimers further are useful to promote re-epithelialization in diseases and conditions such as venous ulcers, ischaemic ulcers (pressure sores), diabetic ulcers, graft sites, graft donor sites, abrasions and burns, diseases of the bronchial epithelium, such as asthma, ARDS, diseases of the intestinal epithelium, such as mucositis associated with cytotoxic treatment, esophageal ulcers (reflux disease), stomach ulcers, small 15 intestinal and large intestinal lesions (inflammatory bowel disease).

15 The scFv-Fc dimers also may be used to promote endothelial cell proliferation, for example, in stabilizing atherosclerotic plaques, promoting healing of vascular anastomoses, or to inhibit smooth muscle cell proliferation, such as in arterial disease, restenosis and asthma.

20 The scFv-Fc dimers are useful to enhance the immune response to macrophage-mediated infections. They are also useful to reduce immunosuppression caused, for example, by tumors, AIDS, or granulomatous diseases. The scFv-Fc dimers are useful to treat hyperproliferative diseases, such as cancers including, but not limited to, breast, prostate, ovarian, stomach, renal, pancreatic, colorectal, skin, lung, cervical and bladder 25 cancers, glioma, mesothelioma, as well as various leukemias and sarcomas, such as Kaposi's sarcoma, and are useful to treat or prevent recurrences or metastases of such tumors. The scFv-Fc dimers of the invention also are useful to inhibit cyclosporin-mediated metastases.

In the context of cancer therapy, "treatment" includes any medical intervention resulting in the slowing of tumor growth or reduction in tumor metastases, as well as partial remission of the cancer in order to prolong life expectancy of a patient.

30 Methods of treatment comprise administering a scFv-Fc dimer or pharmaceutical compositions comprising the scFv-Fc dimer. The scFv-Fc dimers may be used in the manufacture of a medicament for administration. For example, a method of making a

medicament or pharmaceutical composition comprises formulating a scFv-Fc dimer with a pharmaceutically acceptable excipient. A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

5 Administration is preferably in a “therapeutically effective amount” sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom of a particular disease or condition. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of the disease or condition being treated. Prescription of treatment, e.g., decisions on dosage etc., may
10 be determined based on preclinical and clinical studies the design of which is well within the level of skill in the art.

15 The precise dose will depend upon a number of factors, including whether the scFv-Fc dimer is for diagnosis or for treatment, the size and location of the area to be treated, and the nature of any detectable label or other molecule attached to the scFv-Fc dimer. A typical dose of a scFv-Fc dimer, for example, can be in the range 100 µg to 1 gram for systemic applications, and 1 µg to 1 mg for topical applications. The dose for a single treatment of an adult patient may be adjusted proportionally for children and infants. Treatments may be repeated at daily, twice-weekly, weekly, monthly or other intervals, at the discretion of the physician. Treatment may be periodic, and the period
20 between administrations is about two weeks or more, preferably about three weeks or more, more preferably about four weeks or more, or about once a month.

25 Dose levels of about 0.1, 0.3, 1, 3, 10, or 15 mg per kg body weight of the patient are expected to be useful and safe. For example, 0.5-5 mg/kg in rat and mouse has been an effective dose in an acute setting. Therefore, for long-term dosing, 0.3-10 mg/kg may be administered to humans, based on an expected half-life of 21 days. Doses may be sufficient for efficacy, while low enough to facilitate optimal administration. For example, a dose of less than 50 mg facilitates subcutaneous administration. Intravenous administration may be used as the route of delivery for severe diseases, where high doses and the long dosing intervals may be required. Subcutaneous injection can increase the potential immune response to a product. Local administration for localized disease can
30

reduce the amount of administered product and increase the concentration at the site of action, which can improve safety.

The scFv-Fc dimers of the invention may be administered by injection, for example, subcutaneously, intravenously, intracavity (e.g., after tumor resection), 5 intralesionally, intraperitoneally, or intramuscularly. ScFv-Fc dimers also may be delivered by inhalation or topically (e.g., intraocular, intranasal, rectal, into wounds, on skin), or orally.

A scFv-Fc dimer will usually be administered in the form of a pharmaceutical composition, which may comprise at least one component in addition to the scFv-Fc 10 dimer. Thus pharmaceutical compositions may comprise a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. Such materials could include, for example, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic, and absorption 15 delaying agents. Some examples of pharmaceutically acceptable carriers are water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, as well as combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols, such as mannitol, sorbitol, or sodium chloride in the composition. Additional examples of pharmaceutically acceptable substances are wetting 20 agents or auxiliary substances, such as emulsifying agents, preservatives, or buffers, which increase the shelf life or effectiveness.

The precise nature of the carrier or other material will depend on the route of administration. For intravenous injection, or injection at the site of affliction, the active 25 ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pK, isotonicity, and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as sodium chloride injection, Ringer's injection, and lactated Ringer's injection. Preservatives, stabilizers, buffers, antioxidants, and/or other additives may be included.

A scFv-Fc dimer may be formulated in liquid, semi-solid, or solid forms, such as 30 liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, powders, liposomes, and suppositories. The preferred form depends on the intended

mode of administration, the therapeutic application, the physicochemical properties of the molecule, and the route of delivery. Formulations may include excipients, or combinations of excipients, for example: sugars, amino acids and surfactants. Liquid formulations may include a wide range of scFv-Fc dimer concentrations and pH. Solid 5 formulations may be produced by lyophilization, spray drying, or drying by supercritical fluid technology, for example.

Therapeutic compositions can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the scFv-Fc dimer in an 10 appropriate solvent with one or a combination of ingredients enumerated above, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are 15 vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by using a coating such as lecithin, by maintaining the particle size of a dispersion, or by using surfactants. Prolonged absorption of injectable compositions can be brought about by including in the 20 composition an agent that delays absorption, for example, monostearate salts and gelatin.

In certain embodiments, the active compound may be prepared with a carrier that will protect the scFv-Fc dimer against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl 25 acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.

A method of using a scFv-Fc dimer may comprise causing or allowing binding to TGF β . Such binding may take place *in vivo*, e.g., following administration of a scFv-Fc 30 dimer to a patient, or it may take place *in vitro*, e.g., in ELISA, Western blotting, immunocytochemistry, immunoprecipitation, affinity chromatography, or cell based

assays, or in *ex vivo* based therapeutic methods, e.g., methods in which cells or bodily fluids are contacted *ex vivo* with a scFv-Fc dimer and then administered to a patient.

5 A kit comprising a scFv-Fc dimer is described. The scFv-Fc dimer may be labeled to allow its reactivity in a sample to be determined. Kits may be employed in diagnostic analysis, for example. A kit may contain instructions for use of the components. Ancillary materials to assist in or to enable performing such a method may be included within the kit.

10 The reactivity of a scFv-Fc dimer in a sample may be determined by any appropriate means, e.g., radioimmunoassay (RIA). Radioactively labeled antigen may be mixed with unlabeled antigen (the test sample) and allowed to bind to the scFv-Fc dimer. Bound antigen is physically separated from unbound antigen and the amount of radioactive antigen bound to the scFv-Fc dimer is determined. A competitive binding assay also may be used with non-radioactive antigen, using an antigen or an analogue linked to a reporter molecule. The reporter molecule may be a fluorochrome, phosphor, 15 or dye. Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red. Suitable chromogenic dyes include diaminobenzidine.

20 Other reporters include macromolecular colloidal particles or particulate material such as latex beads that are colored, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded. These molecules may be enzymes that catalyze reactions that develop or change colors or cause changes in electrical properties, for example. They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors. 25 Biotin/avidin or biotin/streptavidin and alkaline phosphatase detection systems may be employed. The signals generated by antibody-reporter conjugates may be used to derive quantifiable absolute or relative data of the relevant antibody binding in samples.

30 Also described is the use of a scFv-Fc dimer for measuring antigen levels in a competition assay. The scFv-Fc dimer can be linked to a reporter molecule so that a physical or optical change occurs on binding, for example. The reporter molecule may directly or indirectly generate detectable, and preferably measurable, signals. The

reporter molecules may be linked directly or indirectly, covalently, e.g., via a peptide bond or non-covalently. The scFv-Fc dimer and a protein reporter may be linked by a peptide bond and recombinantly expressed as a fusion protein.

Further aspects and embodiments of the present invention will be apparent to
5 those skilled in the art in the light of the present disclosure, including the following
experimental exemplification.

Examples

Example 1: Affinity and Potency of scFv and IgG4 Antibody

CAT192(IgG4) (metelimumab) is a human IgG4 monoclonal antibody that
10 selectively neutralizes TGF- β 1. TGF β 1 (20-600RU) was immobilized to a CM5 chip on
Biacore using NHS/EDC chemistry. Various amounts of CAT192(IgG4) were injected
over the surface to monitor the binding to TGF β 1 determined by surface plasmon
resonance. The data were analyzed with a 1:1 binding model to determine binding
constants. CAT192(IgG4) was found to bind TGF β 1 with relatively low affinity as
15 determined by surface plasmon resonance, when compared to the binding by the parental
CAT191scFv as shown in FIG.2. CAT192(IgG4) also showed a relatively low efficacy
(IC₅₀ = ~10 nM) in an A549 cell-based potency assay, which measured inhibition of
TGF β 1-stimulated IL-11 production. Representative results of an A549 assay are shown
in FIG. 3. The A549 assay was conducted according to the procedure disclosed in
20 Rapoza et al. (2006) “Development of an in vitro potency assay for therapeutic TGF β
antagonists: the A549 cell bioassay,” *J. Immunol. Methods* 316: 18-26. While an
apparent dissociation constant of ~10 nM showed specific binding to TGF β 1, therapeutic
applications of CAT192 (IgG4) would benefit from a higher relative potency.

Example 2: Modified IgG1 Antibody

CAT192(IgG4) affinity can be slightly enhanced by certain denaturing conditions,
25 suggesting that antibody folding may have caused the loss of affinity during the
conversion of scFv to IgG4. IgG4 folding has been proposed to be unique (Aalberse and
Schuurman “IgG4 breaking the rules”, *Immunology* 105:9-19). The Fab arm exchange in
IgG4 and the interaction of Fabs with Fc CH2 domain may possibly explain this loss of
30 affinity by CAT192(IgG4). Therefore, CAT192 was remodeled to produce the IgG1

version by replacing IgG4 Fc (CH1, CH2 and CH3 domains) with the consensus IgG1 sequence. The DNA coding the CAT192 (IgG1) was synthesized from GeneArt and subcloned into expression vector pCEP4(-E+I)Dest.

CAT192(IgG1) was produced from HEK293 transfection and purified with 5 Protein A column. Remodeling CAT192 from IgG4 to IgG1, however, did not increase its affinity. Fab fragments generated from the IgG1 and IgG4 did not increase its affinity either. It was concluded that the high affinity of CAT191(scFv) (SEQ ID NO: 12) was lost during conversion to a full-length antibody format, whether it was a IgG1 or IgG4. This was unexpected, because scFv components obtained from a library are often 10 engineered to a full-length IgG format for therapeutic development.

Example 3: Various Dimer Designs

CAT191(scFv) (SEQ ID NO: 12) was found to bind TGF β 1 with high affinity, using surface plasmon resonance, but CAT191(scFv) lacked the avidity needed for 15 effective neutralization of TGF β 1. Accordingly, various other formats were tested, using the scFv component as a basic building block. General formats of antibody fragments, including the tested formats, are depicted in FIG. 1.

Tested formats included a diabody, a peptide-derived dimer (*e.g.*, a leucine zipper peptide-derived dimer), and an scFv-Fc dimer. scFv CAT191 diabody had the 20 (Gly4Ser)3-type linker replaced with a short 5aa linker (GSSGG) (SEQ ID NO: 19) to create a non-covalent divalent binder (diabody dimer). Each monomer had the sequence set forth in SEQ ID NO: 14. Each monomer of the leucine zipper peptide-derived dimer had the sequence set forth in SEQ ID NO: 16. Finally, each monomer of the scFv-Fc dimer had the sequence set forth in SEQ ID NO: 9. The diabody and the peptide derived dimer were expressed in E. Coli and the scFv-Fc was expressed in HEK293 cells.

25 The leucine zipper peptide-derived dimer was difficult to express, and the partially purified dimer only showed intermediate affinity, as measured by surface plasmon resonance. The diabody (scFv 5aa) only showed intermediate affinity, but no avidity. By contrast, a scFv-Fc dimer produced from transient HEK293 transfection was found to bind to TGF β 1 specifically with high affinity and avidity. The binding results 30 expressed as apparent dissociation constants obtained with surface plasmon resonance are summarized below in Table 2.

Table 2: Binding Results for scFv-Fc Dimer

Sample	24 RU TGF β 1 K_D (nM)	105 RU TGF β 1 K_D (nM)	544 RU TGF β 1 K_D (nM)
scFv-Fc	0.5	0.2	0.09
CAT191 scFv	1.7	1.6	1.3
scFv 5aa	4.1	3.9	4.8

Avidity**No Avidity**

The TGF β 1 neutralizing potency of various formats was also compared in the 5 A549 cell-based bioassay. FIG. 3 shows the A549 bioassay results for the diabody (“scFv diabody 5aa”), CAT191(scFv) (“scFv”), the scFv-Fc dimer (“CAT191(scFv-Fc”), and CAT192(IgG4) (“CAT192”). As seen in FIG. 3, the scFv-Fc dimer demonstrated an apparent dissociation constant in this assay over four orders of magnitude lower than CAT192 ($\sim 10^{-3}$ nM versus $\sim 10^1$ nM).

10 Example 4: scFv-Fc Clone

CAT191(scFv-Fc) was cloned and produced in larger scale in CHO cells. CAT191 scFv-Fc coding sequence was PCR amplified from a pCEP4 based expression vector using a gene specific forward and reverse primer set. As part of the PCR amplification the following changes were introduced to the CAT191 scFv-Fc coding 15 sequence: 1) addition of endonuclease sites at the 5' and 3' ends, 2) addition of Kozak consensus sequence immediately upstream of the start codon, 3) change of the “TAG” stop codon to “TAA”, and 4) mutation of the thymidine 4 nucleotides upstream of the stop codon to a guanosine thus eliminating an endogenous splice donor site. The splice donor site mutation did not result in an amino acid change.

20 The PCR amplified CAT191 coding sequence was subcloned into a shuttle vector to facilitate sequence verification and molecular cloning. After sequence verification, the CAT191 coding sequence was cloned into Genzyme expression vectors pGZ600 and pGZ620. Both vectors used the hamster β -actin promoter to drive expression of the CAT191 transgene. They also contained the DHFR selectable marker that was driven by 25 a separate promoter (SV40) to enable selection in CHO cells. CHO-8D6 host cell line was transfected with either the pGZ600-CAT191 or pGZ620-CAT191 expression plasmid. Following a brief recovery period, the transfected cells were placed into

nucleotide-deficient growth medium for selection to generate pools of stable transfectants. After pools recovered from selection, a second round of selection was performed in the presence of 20nM methotrexate. The CHO pools selected this way was scaled up and the conditioned media was used for purification using Protein A column.

5 The CHO cell-produced protein was characterized by SDS-PAGE, Biacore binding, SEC-HPLC, and the A549 cell potency assay. The results confirmed that the scFv-Fc dimer had a higher affinity and potency, and it specifically neutralized TGF β 1. The potency compared favorably to the pan-specific GC1008 antibody (FIG. 6 and FIG. 7).

10 **Example 5: Circulation Half-Life**

The circulation half-life of CAT191(scFv-Fc) was tested in a mouse model using the study design depicted in Table 3.

Table 3: Circulation Half-Life of scFv-Fc Dimer

Group	Animal #'s	Test Article	Dose (mg/kg)	Dose Route	Time Points
1	1 – 8	scFv-Fc	1.0	IP	2, 6, 24, 72, 144, 240, and 336 hours post-dose
2	9-16	scFv-Fc	1.0	IV	0.25, 6, 24, 72, 144, 240, and 336 hours post-dose

15 Blood was drawn from the retro-orbital plexus at the specified times after intraperitoneal (IP) or intravenous (IV) administration. Approximately 60 μ L of whole blood was collected into hematocrit tubes and processed for serum. All samples was stored at -80°C until analysis. The CAT191(scFv-Fc) concentration was determined by ELISA. The results of this pharmacokinetic study are depicted in FIG. 4 and FIG. 5. The results suggested a circulation half-life of 1.5-2.0 days, much longer than that for a typical scFv molecule, which is several hours.

20 **Example 6: scFv-Fc Dimer Stability**

The stability of CAT191(scFv-Fc) stored at -80°C was monitored for a year by SEC-HPLC, Biacore TGF β 1 binding, and the A549 potency assay. No change in aggregation, affinity, or potency was observed during the test period. Material stored at 4°C displayd a slight but steady increase in aggregation over 1 year. The unique

combination of the smaller size, high selectivity, potency against TGF β 1, and long *in vivo* half-life made CAT191(scFv-Fc) an ideal candidate for therapeutic applications.

All documents cited throughout this disclosure, including but not limited to scientific publications, patents and publication of patent applications, are hereby 5 incorporated by reference in this disclosure as if the full contents are reproduced herein.

SEQUENCE LISTING

SEQ ID No. 1: Human IgG1 VH domain Clone SL15 (SQN4 US6492497)

EVQLVESGGGVVQPGRSRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISY
DGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDT
10 DPQYSWGQGTTVTVSS

SEQ ID No. 2: Human IgG1 VH domain Clone JT182 (SQN10 US6492497)

QVQLVESGGGVVQPGRSRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISY
DGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDT
15 PASPDWGQGTTVTVSS

SEQ ID No. 3: Synthetic linker

SGGGSGGGGSGGGGS

20 **SEQ ID No. 4: Synthetic linker**

GGGGSGGGGSGGGGS

SEQ ID No. 5: Human IgG1 V κ domain Clone SL15A: (SQN6 US6492497)

EIVLTQSPSSLASAVGDRVITCRASQGIGDDLGVYQQKPGKAPILLIYGTSTLQS
25 GVPSRFSGSGSGTDFLTINSLQPEDFATYYCLQDSNYPLTFGGGTRLEIK

SEQ ID No. 6: Human IgG1 V κ domain Clone SL15S: (SQN8 US6492497)

EIVLTQSPSSLASAVGDRVITCRSSQGIGDDLGVYQQKPGKAPILLIYGTSTLQSG
VPSRFSGSGSGTDFLTINSLQPEDFATYYCLQDSNYPLTFGGGTRLEIK
30

SEQ ID No. 7: Human IgG1 hinge region

PKSCDKTHTCPPCPAPELLGGP

SEQ ID No. 8: Human IgG1 Fc region

35 SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR
EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP

QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID No. 9: CAT191(scFv-Fc)

5 EVQLVESGGGVVQPGRSRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISY
DGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDT
DPQYSWGQGTTVTVSSSGGGSGGGGGSEIVLTQSPSSLSASVGDRVTITCR
SSQGIGDDLWYQQKPGKAPILLIYGTSTLQSGVPSRFSFGSGSGTDFLTINSLQPE
DFATYYCLQDSNYPLTFGGGTRLEIKGGSGPKSCDKTHTCPPCPAPELLGGPSVF
10 LFPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIASKAKGQPREPVY
TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSF
FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

15 **SEQ ID No. 10: CAT192 (IgG4) Light Chain**

EWLTQSPSSLSASVGDRVTITCRASQGIGDDLWYQQKPGKAPILLIYGTSTLQS
GVPSRFSGSGSGTDFLTINSLQPEDFATYYCLQDSNYPLTFGGGTRLEIKRTVAA
PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
20 DSKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID No. 11: CAT192 (IgG4) Heavy Chain

EVQLVESGGGVVQPGRSRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISY
DGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDT
DPQYSWGQGTTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTV
25 SWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTCNVDHKPSNTKV
DKRVESKYGPPCPSCPAPEFLGGPSVFLPPKPKDLMISRTPEVTCVVVDVSQED
PEVQFNWYVDGVEVHNAKTPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCK
VSNKGLPSSIEKTISKAKGQPREPVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA
30 VEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL
HNHYTQKSLSLSLGK

SEQ ID No. 12: CAT191(scFv)

EVQLVESGGGVVQPGRSRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISY
DGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDT
35 DPQYSWGQGTTVTVSSSGGGSGGGGGSEIVLTQSPSSLSASVGDRVTITCR
SSQGIGDDLWYQQKPGKAPILLIYGTSTLQSGVPSRFSFGSGSGTDFLTINSLQPE
DFATYYCLQDSNYPLTFGGGTRLEIK

SEQ ID No. 13: Diabody-5aa encoding nucleic acid

40 atgaccatgattacgccaagcttggagcccttttggagatttcaacgtaaaaattatttcgcatttcgttttagttgtcccttc
tatgcggcccagccggccatggccgagggtcagctggtagtggggaggcgtggccagcctggaggtccctgaga
ctctcctgtgcagcctctggattcacccatgttcagtagctatggcatgcactggccggcaggctccaggcaaggagctggagtg

5 gtggcagttatatcatatgtgaagtattaaatactatgcagactccgtgaagggccgattcaccatctccagagacaattccaa
 gaacacgctgtatctgcaaataaacagcctgagagctgaggacacggctgttactgtgcgcgaactgtgaatatagtgg
 ctacgatacggacccccagactcctggggcaagggaccacggcaccgtctcaggccctctggcggtaaaattgtct
 10 gactcgtctccatcctccgtctgcacatgttaggagacagactcaccatcactgcccgtcaagtgcggcattggagatgatt
 gggctggatcagcagaagccaggaaagccctatcctctgtatctgttacatccacttacaaagtgggtccgtcaag
 gttcagcggcagtggatctggcacagatttcacttcaccatcaacagcctgcagccctgaagatttgcaacttattactgtctaca
 agattccaattaccgctcacttccggcggagggacacgactggagattaaacgtgcggccgcacatcatcaccatcaagg
 15 ggcgcagaacaaaaactcatctcagaagaggatctgaatggggccgcatagtagctcgagatcaaacggctagccagcca
 gaactcgccccgaaagaccccgaggatgtcgagcaccaccaccac

SEQ ID No. 14: Diobody-5aa

EVQLVESGGVVQPGRLRLSCAASGFTESSYGMHWVRQAPGKELEWVAVISY
 DGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDT
 15 DPQYSWQGQTTVTVSSGSSGEIVLTQSPSSLSASVGDRVITCRSSQGIGDDLW
 WYQQKPGKAPILLIYGTSTLQSGVPSRFSGSQTDFTLTINSLQPEDFATYYCLQ
 DSNYPLTFGGGTRLEIKRAAAHHHHHGAAEQLISEEDLNGAA

SEQ ID No. 15: Leucine zipper peptide-derived dimer encoding nucleic acid

20 gagggtcagctggtgagactggggaggcggtggccagcctggaggccctgagacttcctgtgcagccctctggattcac
 cttagtgcattggcatgcactgggtccgcaggctccaggcaaggagctggagtggtggcagttatcatatgtgaag
 tattaaatactatgcagactccgtgaagggccgattcaccatctccagagacaattccaagaacacgcgtatctgcaaata
 25 gcctgagagctgaggacacggcgtgttactgtgcgcgaactggtaatatagtggctacgatacggcccccagactcct
 gggggcaagggaccacggcaccgtctcaagtggaggcggtcaggcggaggtggcagcggcgtggcggatcgaa
 attgtgcactcacttcacccctgtgcacatctgttaggagacagactcaccatcacttgcggtaagtcaggcattgg
 30 gatgatttggctgttatcagcagaagccaggaaagccctatcctctgtatgttacatccacttacaaagtgggtccc
 gtcaagggtcagcggcagtggatctggcacagatttcacttcaccatcaacgcctgcagccctgaagatttgcaacttattactg
 tctacaagattccaattaccgcacttccgggagggacacgactggagattaaacgtgcggccgcacatcatcaccat
 cacggggccgcagaacaaaaactcatctcagaagaggatctgaatggggccgcaccaagccacttaccccccaggtctt
 caggcgaactgaaactgctgaaacatctgaaactgctgaaaggcccgtaaaggcgaactgaaactgctgaa
 acatctgaaagaactgctgaaaggcggtgcgcggcgtcatcatcaccatcat

SEQ ID No. 16: Leucine zipper peptide-derived dimer

EVQLVESGGVVQPGRLRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISY
 DGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDT
 35 DPQYSWQGQTTVTVSSGGGGGGGGGGSEIVLTQSPSSLSASVGDRVITCR
 SSQGIGDDLWYQQKPGKAPILLIYGTSTLQSGVPSRFSGSQTDFTLTINSLQPE
 DFATYYCLQDSNYPLTFGGGTRLEIKRAAAHHHHHGAAEQLISEEDLNGAAP
 KPSTPPGSSGELEELLKHLKELLKGPRKGELEELLKHLKELLKGAPGGHHHHHH

40 **SEQ ID No. 17: CAT191(scFv-Fc) encoding nucleic acid**

gagggtcagctggtgagactggggaggcggtggccagcctggaggccctgagacttcctgtgcagccctctggattcac
 cttagtgcattggcatgcactgggtccgcaggctccaggcaaggagctggagtggtggcagttatcatatgtgaag
 tattaaatactatgcagactccgtgaagggccgattcaccatctccagagacaattccaagaacacgcgtatctgcaaata

gcctgagagctgaggacacggctgttattactgtgcgcgaactggtaataatggctacgatacggaccccccagtactcct
ggggcaagggaccacggtcaccgtcctcaagtggaggcggttcaggcggaggtggcagcggcgtggcggatcggaa
attgtgctgactcagtctccatcctccctgtcatctgtaggagacagagtcaccatcacttgccggtaagtcagggcatttga
gatgatttggcgttgtatcagcagaagccaggaaagccctatcctctgatcatgttacaaatgggtttcc
5 gtcaagggtcagcggcagtggatctggcacagattcacttcaccatcaacagcctgcagcctgaagatttgcacttattactg
tctacaagattccaattacccgctcacttcggcggagggacacgactggagatcaaagggtggcagcggacctaatttgcac
aaaactcacacatgcccaccgtgcccagcacctgaactctggggggaccgtcagtcctcttcccccaaaaccaaggac
accctcatgtatcccgacccctgaggtcacatgcgtgggtggacgtgagccacgaagaccctgaggtaagttcaactg
10 gtacgtggacggcgtggagggtgcataatgccaagacaagccggggaggagcagtaacacagcacgtaccgtgtggcag
cgtcctcaccgtcctgcaccaggactggtaatggcaaggagtacaagtgcacggatccaaacccctccaggccccca
tcgagaaaaccatctccaaagccaaagggcagccccgagaaccacagggttacaccctgccccatccggatgagctgac
caagaaccaggcgcacgtgcctggtaaaggcttatcccgacatgcgtggagtgaaatggcag
15 ccggagaacaactacaagaccacgcctccgtctggactccgacggctccttcccttacagcaagctcaccgtggacaag
agcagatggcagcaggaaacgttctcatgtccgtatgcatgaggctctgcacaaccactacacgcagaagacccttc
cctgtctccggtaatagtag

SEQ ID No. 18: Human TGF β 1

ALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSL
DTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRS
20 CKCS

SEQ ID No. 19

GSSGG

25 **SEQ ID No. 20**

GGSG

SEQ ID No. 21

CPPCP

30

SEQ ID No. 22

SYGMH

SEQ ID No. 23

35 VISYDGSIKYYADSVKG

SEQ ID No. 24

TGEYSGYDTSGVEL

SEQ ID No. 25
TGEYSGYDTDPQYS

5 **SEQ ID No. 26**
TGFYSGYDTPASPD

SEQ ID No. 27
RASQGIGDDLG

10 **SEQ ID No. 28**
GTSTLQS

SEQ ID No. 29
15 LQDSNYPLT

SEQ ID No. 30
TGX₁YSGYDTX₂X₃X₄X₅X₆

20

CLAIMS

1. An isolated binding protein that binds TGF β 1, wherein the isolated binding protein is a dimer formed from a polypeptide chain having the formula of, from N-terminus to C-terminus:

(VH domain)-(linker1)-(VL domain)-(linker2)-(hinge)-(Fc region),

wherein

the VH domain comprises a heavy chain complementarity determining region (HCDR) 1 having the amino acid sequence of SEQ ID NO: 22, an HCDR2 having the amino acid sequence of SEQ ID NO: 23, and an HCDR3 having the amino acid sequence of SEQ ID NO: 24, 25, 26, or 30; and the VL domain comprises a light chain complementarity determining region (LCDR) 1 having the amino acid sequence of SEQ ID NO:27 with an A2S substitution, an LCDR2 having the amino acid sequence of SEQ ID NO: 28, and an LCDR3 having the amino acid sequences of SEQ ID NO: 29;

the linker 1 is a [G₄S]₃-type linker;

the linker 2 is SEQ ID NO: 20 or a variant thereof, wherein the variant differs from

SEQ ID NO: 20 in length by one to four amino acids, or differs from SEQ ID NO: 20 by

having up to two amino acid substitutions from glycine to serine or from serine to glycine; and

the hinge comprises an amino acid sequence from a human IgG₁ or IgG₄ hinge region, or the amino acid sequence of SEQ ID NO: 7 or 21; and

the Fc region is derived from a human IgG1 or a human IgG4.

2. The isolated binding protein of claim 1, wherein
 - the VH domain comprises the human VH domain sequence set forth in SEQ ID NO: 1, or a variant thereof having up to four amino acid modifications; and
 - the VL domain comprises the human V κ domain sequence set forth in SEQ ID NO: 6, or a variant thereof having up to four amino acid modifications.
3. The isolated binding protein of claim 1 or 2, wherein the VH and VL domains comprise the amino acid sequences set forth in SEQ ID NOs: 1 and 6, respectively.
4. The isolated binding protein of any one of claims 1-3, wherein the linker1 comprises the amino acid sequence SGGGSGGGSGGGS (SEQ ID NO: 3) or GGGGSGGGSGGGS (SEQ ID NO: 4).
5. The isolated binding protein of any one of claims 1-4, wherein the linker2 is SEQ ID NO: 20.
6. The isolated binding protein of claim 1, wherein the polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO: 9.
7. The isolated binding protein of any one of claims 1-6, wherein the isolated binding protein has at least one of the following characteristics:
 - a) binding selectively to TGF β 1;

- b) having an IC₅₀ to human TGF β 1 of less than 1 nM in an A549 bioassay;
- c) exhibiting a Kd for human TGF β 1 at least about 50% lower than a Kd for human TGF β 2 as measured by surface plasmon resonance; and
- d) exhibiting a Kd for human TGF β 1 at least about 50% lower than a Kd for human TGF β 3 as measured by surface plasmon resonance.

8. A pharmaceutical composition comprising the isolated binding protein of any one of claims 1-7 and a pharmaceutically acceptable excipient.

9. An isolated polynucleotide encoding the isolated binding protein of any one of claims 1-7.

10. An isolated polynucleotide encoding the isolated binding protein of claim 6, wherein the polynucleotide comprises the sequence set forth in SEQ ID NO: 17.

11. A vector comprising the isolated polynucleotide of claim 9 or claim 10.

12. A host cell comprising the vector of claim 11.

13. The host cell of claim 12, wherein the host cell is a mammalian cell.

14. The host cell of claim 13, wherein the mammalian cell is a Human Embryonic Kidney 293 (HEK293) cell.

15. The host cell of claim 13, wherein the mammalian cell is a Chinese Hamster Ovary (CHO) cell.
16. A method of making an isolated binding protein, comprising culturing the host cell of any one of claims 12-15 under conditions suitable to produce the binding protein.
17. A method of treating a disease characterized by TGF β 1 expression in a human in need thereof, comprising administering to the human a therapeutically effective amount of the isolated binding protein of any one of claims 1-7 or the pharmaceutical composition of claim 8.
18. The method of claim 17, wherein the disease is selected from the group consisting of a fibrotic disease, cancer, and an immune-mediated disease.
19. The method of claim 17, wherein the disease is diffuse cutaneous systemic sclerosis, bone remodeling disease, or kidney disease.
20. Use of the isolated binding protein of any one of claims 1-7 in the preparation of a medicament for treating a disease characterized by TGF β 1 expression in a human in need thereof.

1/5




Fig. 1






Fig. 2

3/5

**Fig. 3**




Fig. 4






Fig. 5

5/5

*Fig. 6*

Inhibition of TGF β 1 by scFv-Fc fusions

*Fig. 7*

SUBSTITUTE SHEET (RULE 26)

578962_SA2-027_Seq_Listing_ST25.txt
SEQUENCE LISTING

<110> Pan, Clark
Qi u, Huawei
Bi rd, Jul ie

<120> SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-Beta1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY

<130> 578962

<150> 62/128133

<151> 2015-03-04

<160> 30

<170> PatentIn version 3.5

<210> 1

<211> 123

<212> PRT

<213> Homo sapiens

<400> 1

Gl u Val Gl n Leu Val Gl u Ser Gl y Gl y Gl y Val Val Gl n Pro Gl y Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Al a Al a Ser Gl y Phe Thr Phe Ser Ser Tyr
20 25 30

Gl y Met His Trp Val Arg Gl n Al a Pro Gl y Lys Gl u Leu Gl u Trp Val
35 40 45

Al a Val Ile Ser Tyr Asp Gl y Ser Ile Lys Tyr Tyr Al a Asp Ser Val
50 55 60

Lys Gl y Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gl n Met Asn Ser Leu Arg Al a Gl u Asp Thr Al a Val Tyr Tyr Cys
85 90 95

Al a Arg Thr Gl y Gl u Tyr Ser Gl y Tyr Asp Thr Asp Pro Gl n Tyr Ser
100 105 110

Trp Gl y Gl n Gl y Thr Thr Val Thr Val Ser Ser
115 120

<210> 2

<211> 123

<212> PRT

<213> Homo sapiens

<400> 2

Gl n Val Gl n Leu Val Gl u Ser Gl y Gl y Gl y Val Val Gl n Pro Gl y Arg
1 5 10 15

578962_SA2-027_Seq_Listing_ST25.txt

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Glu Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Pro Ala Ser Pro Asp
100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 3

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 3

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

<210> 4

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 4

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

<210> 5

<211> 107

<212> PRT

<213> Homo sapiens

<400> 5

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Gly Asp Asp
Page 2

20

578962_SA2-027_Seq_Listing_ST25.txt
25 30

Leu Gl y Trp Tyr Gl n Gl n Lys Pro Gl y Lys Ala Pro Ile Leu Leu Ile
35 40 45

Tyr Gl y Thr Ser Thr Leu Gl n Ser Gl y Val Pro Ser Arg Phe Ser Gl y
50 55 60

Ser Gl y Ser Gl y Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gl n Pro
65 70 75 80

Gl u Asp Phe Ala Thr Tyr Tyr Cys Leu Gl n Asp Ser Asn Tyr Pro Leu
85 90 95

Thr Phe Gl y Gl y Thr Arg Leu Gl u Ile Lys
100 105

<210> 6
<211> 107
<212> PRT
<213> Homo sapiens

<400> 6

Gl u Ile Val Leu Thr Gl n Ser Pro Ser Ser Leu Ser Ala Ser Val Gl y
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gl n Gl y Ile Gl y Asp Asp
20 25 30

Leu Gl y Trp Tyr Gl n Gl n Lys Pro Gl y Lys Ala Pro Ile Leu Leu Ile
35 40 45

Tyr Gl y Thr Ser Thr Leu Gl n Ser Gl y Val Pro Ser Arg Phe Ser Gl y
50 55 60

Ser Gl y Ser Gl y Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gl n Pro
65 70 75 80

Gl u Asp Phe Ala Thr Tyr Tyr Cys Leu Gl n Asp Ser Asn Tyr Pro Leu
85 90 95

Thr Phe Gl y Gl y Thr Arg Leu Gl u Ile Lys
100 105

<210> 7
<211> 22
<212> PRT
<213> Homo sapiens

<400> 7

Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
1 5 10 15

578962_SA2-027_Seq_Listing_ST25.txt

Gl u Leu Leu Gl y Gl y Pro
20

<210> 8
<211> 209
<212> PRT
<213> Homo sapiens

<400> 8

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
1 5 10 15

Arg Thr Pro Gl u Val Thr Cys Val Val Asp Val Ser His Gl u Asp
20 25 30

Pro Gl u Val Lys Phe Asn Trp Tyr Val Asp Gl y Val Gl u Val His Asn
35 40 45

Al a Lys Thr Lys Pro Arg Gl u Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val
50 55 60

Val Ser Val Leu Thr Val Leu His Gl n Asp Trp Leu Asn Gl y Lys Gl u
65 70 75 80

Tyr Lys Cys Lys Val Ser Asn Lys Al a Leu Pro Al a Pro Ile Gl u Lys
85 90 95

Thr Ile Ser Lys Al a Lys Gl y Gl n Pro Arg Gl u Pro Gl n Val Tyr Thr
100 105 110

Leu Pro Pro Ser Arg Asp Gl u Leu Thr Lys Asn Gl n Val Ser Leu Thr
115 120 125

Cys Leu Val Lys Gl y Phe Tyr Pro Ser Asp Ile Al a Val Gl u Trp Gl u
130 135 140

Ser Asn Gl y Gl n Pro Gl u Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
145 150 155 160

Asp Ser Asp Gl y Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
165 170 175

Ser Arg Trp Gl n Gl n Gl y Asn Val Phe Ser Cys Ser Val Met His Gl u
180 185 190

Al a Leu His Asn His Tyr Thr Gl n Lys Ser Leu Ser Leu Ser Pro Gl y
195 200 205

Lys

578962_SA2-027_Seq_Listing_ST25.txt

<210> 9
<211> 480
<212> PRT
<213> Homo sapiens

<400> 9

Gl u Val Gl n Leu Val Gl u Ser Gl y Gl y Gl y Val Val Gl n Pro Gl y Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Al a Al a Ser Gl y Phe Thr Phe Ser Ser Tyr
20 25 30

Gl y Met His Trp Val Arg Gl n Al a Pro Gl y Lys Gl u Leu Gl u Trp Val
35 40 45

Al a Val Ile Ser Tyr Asp Gl y Ser Ile Lys Tyr Tyr Al a Asp Ser Val
50 55 60

Lys Gl y Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gl n Met Asn Ser Leu Arg Al a Gl u Asp Thr Al a Val Tyr Tyr Cys
85 90 95

Al a Arg Thr Gl y Gl u Tyr Ser Gl y Tyr Asp Thr Asp Pro Gl n Tyr Ser
100 105 110

Trp Gl y Gl n Gl y Thr Thr Val Thr Val Ser Ser Ser Gl y Gl y Gl y Ser
115 120 125

Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Gl u Ile Val Leu Thr Gl n
130 135 140

Ser Pro Ser Ser Leu Ser Al a Ser Val Gl y Asp Arg Val Thr Ile Thr
145 150 155 160

Cys Arg Ser Ser Gl n Gl y Ile Gl y Asp Asp Leu Gl y Trp Tyr Gl n Gl n
165 170 175

Lys Pro Gl y Lys Al a Pro Ile Leu Leu Ile Tyr Gl y Thr Ser Thr Leu
180 185 190

Gl n Ser Gl y Val Pro Ser Arg Phe Ser Gl y Ser Gl y Ser Gl y Thr Asp
195 200 205

Phe Thr Leu Thr Ile Asn Ser Leu Gl n Pro Gl u Asp Phe Al a Thr Tyr
210 215 220

Tyr Cys Leu Gl n Asp Ser Asn Tyr Pro Leu Thr Phe Gl y Gl y Gl y Thr
225 230 235 240

Arg Leu Gl u Ile Lys Gl y Gl y Ser Gl y Pro Lys Ser Cys Asp Lys Thr
Page 5

578962_SA2-027_Seq_Listing_ST25.txt

245

250

255

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
 260 265 270

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 275 280 285

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
 290 295 300

Gl u Val Lys Phe Asn Trp Tyr Val Asp Gl y Val Gl u Val His Asn Ala
 305 310 315 320

Lys Thr Lys Pro Arg Gl u Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val
 325 330 335

Ser Val Leu Thr Val Leu His Gl n Asp Trp Leu Asn Gl y Lys Gl u Tyr
 340 345 350

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Gl u Lys Thr
 355 360 365

Ile Ser Lys Ala Lys Gl y Gl n Pro Arg Gl u Pro Gl n Val Tyr Thr Leu
 370 375 380

Pro Pro Ser Arg Asp Gl u Leu Thr Lys Asn Gl n Val Ser Leu Thr Cys
 385 390 395 400

Leu Val Lys Gl y Phe Tyr Pro Ser Asp Ile Ala Val Gl u Trp Gl u Ser
 405 410 415

Asn Gl y Gl n Pro Gl u Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
 420 425 430

Ser Asp Gl y Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
 435 440 445

Arg Trp Gl n Gl n Gl y Asn Val Phe Ser Cys Ser Val Met His Gl u Ala
 450 455 460

Leu His Asn His Tyr Thr Gl n Lys Ser Leu Ser Leu Ser Pro Gl y Lys
 465 470 475 480

<210> 10

<211> 213

<212> PRT

<213> Homo sapiens

<400> 10

Gl u Trp Leu Thr Gl n Ser Pro Ser Ser Leu Ser Ala Ser Val Gl y Asp
 1 5 10 15

578962_SA2-027_Seq_Listing_ST25.txt

Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Glu Ile Glu Asp Asp Leu
20 25 30

Gly Trp Tyr Glu Glu Lys Pro Gly Lys Ala Pro Ile Leu Leu Ile Tyr
35 40 45

Gly Thr Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Pro Glu
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Leu Glu Asp Ser Asn Tyr Pro Leu Thr
85 90 95

Phe Glu Glu Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Glu Leu Lys Ser Gly Thr
115 120 125

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140

Val Glu Trp Lys Val Asp Asn Ala Leu Glu Ser Gly Asn Ser Glu Glu
145 150 155 160

Ser Val Thr Glu Glu Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190

Cys Glu Val Thr His Glu Glu Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205

Asn Arg Gly Glu Cys
210

<210> 11
<211> 450
<212> PRT
<213> Homo sapiens

<400> 11

Glu Val Glu Leu Val Glu Ser Gly Gly Val Val Glu Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

578962_SA2-027_Seq_Listing_ST25.txt

Gly Met His Trp Val Arg Glu Ala Pro Gly Lys Glu Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Asp Pro Glu Tyr Ser
100 105 110

Trp Gly Glu Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175

Pro Ala Val Leu Glu Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205

Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220

Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Glu Glu
260 265 270

Asp Pro Glu Val Glu Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Glu Phe Asn Ser Thr Tyr Arg
290 295 300

578962_SA2-027_Seq_Listing_ST25. txt

Val Val Ser Val Leu Thr Val Leu His Glu Asp Trp Leu Asn Glu Lys
305 310 315 320

Gl u Tyr Lys Cys Lys Val Ser Asn Lys Glu Leu Pro Ser Ser Ile Gl u
325 330 335

Lys Thr Ile Ser Lys Ala Lys Glu Glu Pro Arg Glu Pro Glu Val Tyr
340 345 350

Thr Leu Pro Pro Ser Glu Glu Met Thr Lys Asn Glu Val Ser Leu
355 360 365

Thr Cys Leu Val Lys Glu Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380

Gl u Ser Asn Glu Glu Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400

Leu Asp Ser Asp Glu Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415

Lys Ser Arg Trp Glu Glu Glu Asn Val Phe Ser Cys Ser Val Met His
420 425 430

Gl u Ala Leu His Asn His Tyr Thr Glu Lys Ser Leu Ser Leu Ser Leu
435 440 445

Gl y Lys
450

<210> 12
<211> 245
<212> PRT
<213> Homo sapiens

<400> 12

Gl u Val Glu Leu Val Glu Ser Glu Glu Glu Val Val Glu Pro Glu Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Phe Thr Phe Ser Ser Tyr
20 25 30

Gl y Met His Trp Val Arg Glu Ala Pro Glu Lys Glu Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Glu Ser Ile Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Glu Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

578962_SA2-027_Seq_Listing_ST25.txt

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Asp Pro Gln Tyr Ser
 100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ser Gly Gly Gly Ser
 115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Ile Val Leu Thr Gln
 130 135 140

Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
 145 150 155 160

Cys Arg Ser Ser Gln Gly Ile Gly Asp Asp Leu Gly Trp Tyr Gln Gln
 165 170 175

Lys Pro Gly Lys Ala Pro Ile Leu Leu Ile Tyr Gly Thr Ser Thr Leu
 180 185 190

Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
 195 200 205

Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr
 210 215 220

Tyr Cys Leu Gln Asp Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr
 225 230 235 240

Arg Leu Glu Ile Lys
 245

<210> 13

<211> 984

<212> DNA

<213> Homo sapiens

<400> 13

atgaccatga ttacgccaag cttggagcc tttttttgg agatttcaa cgtaaaaaaa	60
ttattattcg caattccttt agtgttcct ttctatgcgg cccagccggc catggccgag	120
gtgcagctgg tggagtctgg gggaggcgtg gtccagccctg ggaggtccct gagactctcc	180
tgtcagcct ctggattcac cttcagtagc tatggcatgc actgggtccg ccaggctcca	240
ggcaaggagc tggagtgggt ggcagttata tcatatgatg gaagtattaa atactatgca	300
gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac gctgtatctg	360
caa atgaaca gcctgagagc tgaggacacg gctgtgtatt actgtgcgcg aactggtaa	420
tatagtggtc acgatacgga cccccagtagc tcctgggggc aagggaccac ggtcaccgtc	480
tcctcagggtt cctctggcggt tgaaattgtg ctgactcagt ctccatcctc cctgtctgca	540

578962_SA2-027_Seq_Listing_ST25.txt

tctgttaggag	acagagtcac	catcaacttgc	cggtaagtc	aggcattgg	agatgatttg	600
ggctggtatac	agcagaagcc	aggaaagcc	cctatcctcc	tgatctatgg	tacatccact	660
ttacaaagtg	gggtcccgta	aaggttcagc	ggcagttggat	ctggcacaga	tttactctc	720
accatcaaca	gcctgcagcc	tgaagatttt	gcaacttatt	actgtctaca	agattccaaat	780
tacccgctca	ctttcggcgg	aggcacacga	ctggagatta	aacgtgcggc	cgcacatcat	840
catcaccatc	acggggccgc	agaacaaaaa	ctcatctcag	aagaggatct	aatggggcc	900
gcatagtagc	tcgagatcaa	acgggctagc	cagccagaac	tcgccccgga	agaccccgag	960
gatgtcgagc	accaccacca	ccac				984

<210> 14

<211> 262

<212> PRT

<213> Homo sapiens

<400> 14

Gl u	Val	Gl n	Leu	Val	Gl u	Ser	Gl y	Gl y	Gl y	Val	Val	Gl n	Pro	Gl y	Arg
1				5				10					15		

Ser	Leu	Arg	Leu	Ser	Cys	Al a	Al a	Ser	Gl y	Phe	Thr	Gl u	Ser	Ser	Tyr
								25				30			

Gl y	Met	Hi s	Trp	Val	Arg	Gl n	Al a	Pro	Gl y	Lys	Gl u	Leu	Gl u	Trp	Val
						35		40			45				

Al a	Val	Ile	Ser	Tyr	Asp	Gl y	Ser	Ile	Lys	Tyr	Tyr	Al a	Asp	Ser	Val
						50		55		60					

Lys	Gl y	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
					65		70		75				80		

Leu	Gl n	Met	Asn	Ser	Leu	Arg	Al a	Gl u	Asp	Thr	Al a	Val	Tyr	Tyr	Cys
								85		90			95		

Al a	Arg	Thr	Gl y	Gl u	Tyr	Ser	Gl y	Tyr	Asp	Thr	Asp	Pro	Gl n	Tyr	Ser
			100				105					110			

Trp	Gl y	Gl n	Gl y	Thr	Thr	Val	Thr	Val	Ser	Ser	Gl y	Ser	Ser	Gl y	Gl y
						115		120			125				

Gl u	Ile	Val	Leu	Thr	Gl n	Ser	Pro	Ser	Ser	Leu	Ser	Al a	Ser	Val	Gl y
					130			135			140				

Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ser	Ser	Gl n	Gl y	Ile	Gl y	Asp	Asp
					145		150			155			160		

Leu	Gl y	Trp	Tyr	Gl n	Gl n	Lys	Pro	Gl y	Lys	Al a	Pro	Ile	Leu	Leu	Ile
						165		170				175			

578962_SA2-027_Seq_Listing_ST25.txt

Tyr Gly Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 180 185 190

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro
 195 200 205

Gl u Asp Phe Al a Thr Tyr Tyr Cys Leu Gln Asp Ser Asn Tyr Pro Leu
 210 215 220

Thr Phe Gly Gly Thr Arg Leu Gl u Ile Lys Arg Al a Al a Al a His
 225 230 235 240

His His His His Gly Al a Al a Gl u Gl n Lys Leu Ile Ser Gl u Gl u
 245 250 255

Asp Leu Asn Gl y Al a Al a
 260

<210> 15

<211> 984

<212> DNA

<213> Homo sapiens

<400> 15

gaggtgcagc tggggagtc tggggaggc gtggccagc ctggggagtc cctgagactc 60

tcctgtcag cctctggatt cacccatgt agctatggca tgcactgggt ccggccaggct 120

ccaggcaagg agctggagtg ggtggcagtt atatcatatg atggaaatgt taaatactat 180

gcagactccg tgaaggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240

ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gcgaactgg 300

gaatatagtg gctacgatac ggaccccccag tactcctggg ggcaaggac cacggtcacc 360

gtctcctcaa gtggaggcgg ttcaggcgg ggtggcagcg ggggtggcgg atcggaaatt 420

gtgctgactc agtctccatc ctccctgtct gcatctgtat gagacagat caccatca 480

tgccggtaa gtcagggcat tggagatgtat ttggggctgtt atcagcagaa gccaggaa 540

gcccttatcc tcctgatcta tggtacatcc actttacaaa gtggggtccc gtcaaggttc 600

agcggcagtg gatctggcac agatttact ctcaccatca acagcctgca gcctgaagat 660

tttgcaactt attactgtct acaagattcc aattaccgc tcactttcgg cgaggggaca 720

cgactggaga ttaaacgtgc ggccgcacat catcatcacc atcacggggc cgcaagaacaa 780

aaactcatct cagaagagga tctgaatggg gccgcaccca agcccagtac ccccccaggt 840

tcttcaggcg aactggaaga actgctgaaa catctgaaag aactgctgaa aggccgcgt 900

aaaggcgaac tggaagaact gctgaaacat ctgaaagaac tgctgaaagg cggtgcgcgg 960

ggcggcgtatc atcatcacca tcat 984

<210> 16

<211> 328

<212> PRT

578962_SA2-027_Seq_Listing_ST25.txt

<213> Homo sapiens

<400> 16

Gl u Val Gl n Leu Val Gl u Ser Gl y Gl y Gl y Val Val Gl n Pro Gl y Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gl y Phe Thr Phe Ser Ser Tyr
20 25 30

Gl y Met His Trp Val Arg Gl n Ala Pro Gl y Lys Gl u Leu Gl u Trp Val
35 40 45

Al a Val Ile Ser Tyr Asp Gl y Ser Ile Lys Tyr Tyr Al a Asp Ser Val
50 55 60

Lys Gl y Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gl n Met Asn Ser Leu Arg Al a Gl u Asp Thr Al a Val Tyr Tyr Cys
85 90 95

Al a Arg Thr Gl y Gl u Tyr Ser Gl y Tyr Asp Thr Asp Pro Gl n Tyr Ser
100 105 110

Trp Gl y Gl n Gl y Thr Thr Val Thr Val Ser Ser Ser Gl y Gl y Gl y Ser
115 120 125

Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Gl u Ile Val Leu Thr Gl n
130 135 140

Ser Pro Ser Ser Leu Ser Al a Ser Val Gl y Asp Arg Val Thr Ile Thr
145 150 155 160

Cys Arg Ser Ser Gl n Gl y Ile Gl y Asp Asp Leu Gl y Trp Tyr Gl n Gl n
165 170 175

Lys Pro Gl y Lys Al a Pro Ile Leu Leu Ile Tyr Gl y Thr Ser Thr Leu
180 185 190

Gl n Ser Gl y Val Pro Ser Arg Phe Ser Gl y Ser Gl y Ser Gl y Thr Asp
195 200 205

Phe Thr Leu Thr Ile Asn Ser Leu Gl n Pro Gl u Asp Phe Al a Thr Tyr
210 215 220

Tyr Cys Leu Gl n Asp Ser Asn Tyr Pro Leu Thr Phe Gl y Gl y Gl y Thr
225 230 235 240

Arg Leu Gl u Ile Lys Arg Al a Al a Al a His His His His His Gl y
245 250 255

578962_SA2-027_Seq_Listing_ST25.txt

Ala Ala Glu Glu Lys Leu Ile Ser Glu Glu Asp Leu Asn Glu Ala Ala
 260 265 270

Pro Lys Pro Ser Thr Pro Pro Gly Ser Ser Gly Glu Leu Glu Glu Leu
 275 280 285

Leu Lys His Leu Lys Glu Leu Leu Lys Gly Pro Arg Lys Gly Glu Leu
 290 295 300

Gl u Gl u Leu Leu Lys His Leu Lys Gl u Leu Leu Lys Gl y Gl y Ala Pro
 305 310 315 320

Gly Gly His His His His His His
 325

<210> 17

<211> 1446

<212> DNA

<213> Homo sapiens

<400> 17

gaggtgcagc	tttgtggagtc	tgggggaggc	gtggccagc	ctgggaggc	cctgagactc	60
tcctgtcag	cctctggatt	cacccttcagt	agctatggca	tgcactgggt	ccgcccaggct	120
ccaggcaagg	agctggagtg	ggtggcagtt	atatcatatg	atggaagtat	taaatactat	180
gcagactccg	tgaagggccg	attcaccatc	tccagagaca	attccaagaa	cacgctgtat	240
ctgcaaatga	acagcctgag	agctgaggac	acggctgtgt	attactgtgc	gcgaactgg	300
gaatatagtg	gctacgatac	ggaccccccag	tactcctggg	ggcaagggac	cacggtcacc	360
gtctcctcaa	gtggaggcgg	ttcaggcgg	ggtggcagcg	gcgggtggcgg	atcgaaatt	420
gtgctgactc	agtctccatc	ctccctgtct	gcatctgtag	gagacagagt	caccatca	480
tgccggtaa	gtcagggcat	tggagatgat	ttgggctgg	atcagcagaa	gccagggaaa	540
gcccttatcc	tcctgatcta	tggtacatcc	actttacaaa	gtgggtccc	gtcaaggttc	600
agcggcagtg	gatctggcac	agatttact	ctcaccatca	acagcctgca	gcctgaagat	660
tttgcactt	attactgtct	acaagattcc	aattaccgc	tcactttcgg	cgaggaa	720
cgactggaga	ttaaagggtgg	cagcggacct	aatcttgt	acaaaactca	cacatgccca	780
ccgtgccca	cacctgaact	cctgggggga	ccgtcagtct	tcctttccc	cccaaaaccc	840
aaggacaccc	tcatgatctc	ccggaccct	gaggtcacat	gcgtggtggt	ggacgtgagc	900
cacgaagacc	ctgaggtcaa	gttcaactgg	tacgtggacg	gcgtggaggt	gcataatgcc	960
aagacaaagc	cgcgggagga	gcagtacaac	agcacgtacc	gtgtggtcag	cgtcctcacc	1020
gtcctgcacc	aggactggct	gaatggcaag	gagtacaagt	gcaaggctc	caacaaagcc	1080
ctcccagccc	ccatcgagaa	aaccatctcc	aaagccaaag	ggcagccccg	agaaccacag	1140
gtgtacaccc	tgcccccattc	ccgggatgag	ctgaccaaga	accaggtcag	cctgacgtgc	1200
ctggtaaag	gcttctatcc	cagcgacatc	gccgtggagt	gggagagcaa	tggcagccg	1260

578962_SA2-027_Seq_Listing_ST25.txt

gagaacaact	acaagaccac	gcctccgtg	ctggactccg	acggctcctt	cttcctctac	1320
agcaagctca	ccgtggacaa	gagcagatgg	cagcagggga	acgtcttctc	atgctccgtg	1380
atgcatgagg	ctctgcacaa	ccactacacg	cagaagagcc	tctccctgtc	tccggtaaa	1440
tagtag						1446

<210> 18

<211> 112

<212> PRT

<213> Homo sapiens

<400> 18

Ala Leu Asp Thr Asn Tyr Cys Phe Ser Ser Thr Glu Lys Asn Cys Cys
1 5 10 15

Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys Asp Leu Gly Trp Lys Trp
20 25 30

Ile His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly Pro Cys
35 40 45

Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr Ser Lys Val Leu Ala Leu
50 55 60

Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala Pro Cys Cys Val Pro
65 70 75 80

Gln Ala Leu Glu Pro Leu Pro Ile Val Tyr Tyr Val Gly Arg Lys Pro
85 90 95

Lys Val Glu Gln Leu Ser Asn Met Ile Val Arg Ser Cys Lys Cys Ser
100 105 110

<210> 19

<211> 5

<212> PRT

<213> Homo sapiens

<400> 19

Gly Ser Ser Gly Gly
1 5

<210> 20

<211> 4

<212> PRT

<213> Homo sapiens

<400> 20

Gly Gly Ser Gly
1

<210> 21

<211> 5

578962_SA2-027_Seq_Listing_ST25.txt

<212> PRT
<213> Homo sapiens

<400> 21

Cys Pro Pro Cys Pro
1 5

<210> 22

<211> 5

<212> PRT
<213> Homo sapiens

<400> 22

Ser Tyr Gly Met His
1 5

<210> 23

<211> 17

<212> PRT
<213> Homo sapiens

<400> 23

Val Ile Ser Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 24

<211> 14

<212> PRT
<213> Homo sapiens

<400> 24

Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Ser Gly Val Glu Leu
1 5 10

<210> 25

<211> 14

<212> PRT
<213> Homo sapiens

<400> 25

Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Asp Pro Gln Tyr Ser
1 5 10

<210> 26

<211> 14

<212> PRT
<213> Homo sapiens

<400> 26

Thr Gly Phe Tyr Ser Gly Tyr Asp Thr Pro Ala Ser Pro Asp
1 5 10

578962_SA2-027_Seq_Listing_ST25. txt

<210> 27
<211> 11
<212> PRT
<213> Homo sapiens

<400> 27

Arg Ala Ser Gln Gly Ile Gly Asp Asp Leu Gly
1 5 10

<210> 28
<211> 7
<212> PRT
<213> Homo sapiens

<400> 28

Gly Thr Ser Thr Leu Gln Ser
1 5

<210> 29
<211> 9
<212> PRT
<213> Homo sapiens

<400> 29

Leu Gln Asp Ser Asn Tyr Pro Leu Thr
1 5

<210> 30
<211> 14
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (10)..(14)
<223> Xaa can be any naturally occurring amino acid

<400> 30

Thr Gly Xaa Tyr Ser Gly Tyr Asp Thr Xaa Xaa Xaa Xaa
1 5 10